Lymphoma

Data Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators

Definitions developed by ISD Scotland in collaboration with the Lymphoma Quality Performance Indicator Development Group

Version 4.1: July 2022

To be used in conjunction with:

1. Lymphoma Clinical Quality Performance Indicators V4.0 (latest published version)
2. Lymphoma QPI Dataset Validations (Latest published version).
3. Lymphoma Measurability of Quality Performance Indicators (Latest published version)
**Data Definitions for the National Minimum Core Dataset for Lymphoma.**  
*Developed by ISD Scotland, 2013*

---

**DOCUMENT CONTROL SHEET**

**Key Information**

<table>
<thead>
<tr>
<th>Title</th>
<th>Lymphoma Cancer – Data Definitions for Minimum Core Dataset to support the Introduction of Lymphoma QPIs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Published/Issued</td>
<td>July 2022</td>
</tr>
<tr>
<td>Date Effective From</td>
<td>1st October 2020</td>
</tr>
<tr>
<td>Version/Issue Number</td>
<td>V4.1</td>
</tr>
<tr>
<td>Document Type</td>
<td>Guidance</td>
</tr>
<tr>
<td>Document Status</td>
<td>Final</td>
</tr>
<tr>
<td>Standard Audience</td>
<td>NHS staff involved in implementing and recording Lymphoma Cancer Quality Performance Indicators.</td>
</tr>
</tbody>
</table>
| Cross References | Lymphoma Quality Performance Indicators  
| | Lymphoma Measurability of Quality Performance Indicators |
| Author | Public Health Scotland (PHS) |

**Revision History**

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Summary of Changes</th>
<th>Name</th>
<th>Changes Marked</th>
</tr>
</thead>
<tbody>
<tr>
<td>V1.1</td>
<td>December 2013</td>
<td>Changes agreed outwith review to support data collection.</td>
<td>David Early ISD</td>
<td>See page xv</td>
</tr>
<tr>
<td>V1.2</td>
<td>June 2014</td>
<td>Changes agreed outwith review to support data collection.</td>
<td>Jane Garrett ISD</td>
<td>See page xv</td>
</tr>
<tr>
<td>V2.0</td>
<td>September 2104</td>
<td>Changes agreed at 9 month review</td>
<td>Jane Garrett ISD</td>
<td>See page xiv</td>
</tr>
<tr>
<td>V2.1</td>
<td>February 2015</td>
<td>Changes agreed after QA of validation documents</td>
<td>Jane Garrett ISD</td>
<td>See page xiii</td>
</tr>
<tr>
<td>V2.2</td>
<td>January 2016</td>
<td>Changes agreed at Baseline Review and changes agreed outwith review</td>
<td>Jane Garrett ISD</td>
<td>See page xi</td>
</tr>
<tr>
<td>V3.0</td>
<td>December 2017</td>
<td>Changes agreed at Formal Review</td>
<td>Jane Garrett ISD</td>
<td>See page ix</td>
</tr>
<tr>
<td>V3.1</td>
<td>December 2018</td>
<td>Changes agreed outwith review to support data collection.</td>
<td>Jane Garrett ISD</td>
<td>See page ix</td>
</tr>
<tr>
<td>Version</td>
<td>Date</td>
<td>Summary of Changes</td>
<td>Name</td>
<td>Changes Marked</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>---------------</td>
<td>----------------</td>
</tr>
<tr>
<td>V3.2</td>
<td>October 2019</td>
<td>Changes agreed outwith review to support data collection.</td>
<td>Jane Garrett</td>
<td>See page vii</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ISD</td>
<td></td>
</tr>
<tr>
<td>V3.3</td>
<td>August 2020</td>
<td>Addition to dataset during COVID 19 Pandemic and changes agreed outwith review</td>
<td>Jane Garrett</td>
<td>See page vi</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHS</td>
<td></td>
</tr>
<tr>
<td>V3.4</td>
<td>February 2021</td>
<td>Changes agreed outwith review to support data collection and rebranding Updates</td>
<td>Ruth McPherson</td>
<td>See page v</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHS</td>
<td></td>
</tr>
<tr>
<td>V4.0</td>
<td>June 2021</td>
<td>Changes agreed at Formal Review</td>
<td>Ruth McPherson</td>
<td>See page iii</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PHS</td>
<td></td>
</tr>
<tr>
<td>V4.1</td>
<td>July 2022</td>
<td>Changes outwith review</td>
<td>Grant Callahan</td>
<td>See page iii</td>
</tr>
</tbody>
</table>
CONTENTS

PREFACE........................................................................................................... i
NOTES FOR IMPLEMENTATION OF CHANGES........................................... ii
CONVENTIONS ................................................................................................ ii
REVISIONS TO DATASET .................................................................................. iii
CRITERIA FOR INCLUSION OF PATIENTS IN AUDIT ..................................... xvii
DATABASE SPECIFICATION ........................................................................... xviii

Section 1: Demographic Items ...................................................................... 1
Person Family Name ....................................................................................... 2
Person Given Name ........................................................................................ 3
Patient Postcode at Diagnosis {Cancer} .......................................................... 4
Date of Birth ...................................................................................................... 5
Person Sex at Birth .......................................................................................... 6
CHI Number ...................................................................................................... 7

Section 2: Pre-treatment Imaging and Staging Investigations ...................... 8
Date of Referral ................................................................................................ 9
Radiological Staging Investigations Complete {Lymphoma} .......................... 11
Date Radiological Staging Investigations Completed {Lymphoma} .............. 12
Date of Radiology Request ............................................................................. 13
Date Radiological Staging Investigations Reported ..................................... 14
FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) ....................... 15
Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) ................................................................. 16
Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) ................................................................. 17
Date Integrated FDG-PET/CT (PET/CT) Scan Reported ............................ 18
Date MYC Testing Reported [DLBCL/Burkitts Lymphoma] ....................... 19
MYC Testing Result [DLBCL/Burkitts Lymphoma] ..................................... 20
Date BCL2/6 Testing Reported ...................................................................... 21
Location of Diagnosis {Cancer} ...................................................................... 22
Date of Diagnosis {Cancer} .......................................................................... 23
Virological Testing (1-3) ................................................................................ 25
Date of Virological Testing (1-3) ................................................................... 26
Date Discussed by Haematology Care Team (MDT) .................................... 27
Date Discussed by Specialist MDT [Primary Cutaneous Lymphoma] ......... 28
COVID 19 Impact ........................................................................................... 29
WHO/ ECOG Performance Status ................................................................. 30
Treatment Intent ............................................................................................ 31
Type of First Cancer Treatment {Lymphoma} .............................................. 32
Date of First Cancer Treatment {Lymphoma} .............................................. 33

Section 3: Pathology ..................................................................................... 34
Date of Issue of Pathology Report {Lymphoma} .......................................... 35
Morphology of Tumour {Lymphoma} ............................................................ 36
Number of Nodal Sites {Lymphoma} .............................................................. 39
Number of Extranodal Sites {Lymphoma} ...................................................... 40
Serum LDH ..................................................................................................... 41
Haemoglobin ................................................................................................. 42
Albumin at Diagnosis .................................................................................... 43
WBC Total ....................................................................................................... 44
WBC Differential – Lymphocytes ................................................................... 45

Section 4: Classification .............................................................................. 46

Data Definitions for the National Minimum Core Dataset for Lymphoma.
Developed by ISD Scotland, 2013
IPI {Lymphoma} ................................................................. 47
FLIPI {Lymphoma} ............................................................. 48
Hasenclever Index for Hodgkin Disease {Lymphoma} ...................... 49
Cotswold Clinical Stage {Lymphoma} ........................................ 50
B Symptoms {Lymphoma} ....................................................... 51
Manchester Stage {Lymphoma} ................................................. 52
Bulk Disease ........................................................................... 53

Section 5: Oncology Treatment ................................................. 54
Location Code {Oncology Treatment} ......................................... 55
Radiotherapy {Lymphoma} ........................................................ 56
Date Treatment Started {Cancer} (Radiotherapy) ......................... 57
Date Treatment Completed {Cancer} (Radiotherapy) .................... 58
Type of Systemic Anti-Cancer Therapy (SACT) ......................... 59
Total Number of Systemic Anti-Cancer Therapy Cycles Planned (SACT) 60
Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT) 61
Anti-B Cell Monoclonal Antibody Therapy {Lymphoma} ............... 62
Rituximab + CHOP {Lymphoma} ............................................... 64
ABVD Chemotherapy {Lymphoma} ............................................. 65
BEACOPP/BEACOPP/BEACOPP/BEACOPP Chemotherapy {Lymphoma} 66
Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer} .......... 67
Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} ..... 68
Date of Final Systemic Anti-Cancer Therapy (SACT) Treatment .......... 69
Date Started Cycle 2 ABVD/BEACOPP/BEACOPP/BEACOPP Chemotherapy {Lymphoma} 70
Date Started Cycle 3 Chemotherapy {Lymphoma} ......................... 71
Date of Interim PET CT Scan {Lymphoma} ................................. 72
Date Interim PET CT Scan Reported ......................................... 73
Maintenance Therapy {Lymphoma} .............................................. 74
Bone Marrow Transplant .......................................................... 75
Date of Radiological Imaging Post Treatment Completed {Lymphoma} .... 76

Section 6: Clinical Trial Entry .................................................. 77
Patient Entered into Clinical Trial {Lymphoma} ............................ 78

Section 7: Follow-up .............................................................. 79
Response Post First Treatment .................................................. 80
Post-Treatment Assessment Date .............................................. 81
Follow-up Status ..................................................................... 82
Follow-up Date/Date of Relapse/Progression ............................... 83
Transformation to High Grade ................................................... 84

Section 8: Death Details ............................................................ 85
Date of Death ........................................................................... 86
PREFACE

Following the publication of Better Cancer Care: An Action Plan in October 2008, the Scottish Government established the Scottish Cancer Taskforce to oversee its implementation. The NHS Scotland Healthcare Quality Strategy in 2010 expands on this by articulating quality ambitions. A quality measurement framework has been developed setting out measures and targets which will be used to monitor, challenge, manage and report progress. Part of this strategy is the development of quality performance indicators (QPIs) to drive quality improvement in cancer care throughout NHS Scotland.

As high quality data are required to enable comparisons over time and between regions, it is important that national data definitions are used to facilitate consistent data collection. National data definitions already in use have been used as much as possible to allow electronic data capture, thereby minimising duplication of data collection. Where national data definitions do not already exist, definitions used in other systems have been incorporated.

To ensure that findings are comparable across Scotland, the national dataset and data definitions in conjunction with the final quality performance indicators were agreed through public engagement and are now ready for implementation for patients diagnosed from 1 October 2014.
NOTES FOR IMPLEMENTATION OF CHANGES

The following changes should be implemented for all patients who are diagnosed with Lymphoma cancer on or after 1 October 2014 who are eligible for inclusion in the Lymphoma cancer audit.

Changes to definitions fall into the following categories:

- to address problems with ongoing audit and standardise data definitions, where feasible, between different cancer sites
- to address problems with existing definitions
- to allow Quality Improvement Indicators to be measured and reported against

General enquiries on the collection of the National Minimum Core Dataset:

If you have difficulties in using individual definitions within this document, or any comments on the attached data definitions, Public Health Scotland would welcome your feedback. Please contact: phs.canceraudit@phs.scot

CONVENTIONS

In the following definitions the layout for each item is standard. Two conventions have been used in the document as follows:

- {curly brackets} - definition relates to one specific named data set
- ‘described elsewhere’ - indicates there is a definition for the named item within this document
REVISIONS TO DATASET

The following addition has been made to facilitate the recording of data.

Revisions to data set outwith review changes (July 2022)

Date BCL2/6 Testing Reported BCLDATE – notes for user updated ‘Not applicable and Test not done are both covered by 10/10/1900’

Date of Referral – Definition & Table of guidance updated with ‘If patient is initially seen by a non-haematological specialty for investigation of lymphadenopathy (eg head and neck or general surgery) then the date of the initial GP referral should be recorded and NOT the date the patient was subsequently referred to haematology.’

Revisions to Data set following Formal Review (June 2021)

Database Specification

Date BCL2/6 Testing Reported – add new Data Item, Field Name: BCLDATE, Field Type: Date (DD/MM/CCYY), Field Length: 10

Date of Issue of Pathology Report {Lymphoma} – add new Data Item, Field Name: DPATHREP, Field Type: Date (DD/MM/CCYY), Field Length: 10

BEACOPP/BEACOPDac Chemotherapy {Lymphoma} – add new Data Item, Field Name: BEACOPP, Field Type: Integer, Field Length: 2

Date of Final Systemic Anti-Cancer Therapy (SACT) Treatment – add new Data Item, Field Name: SACTFINALDATE1, Field Type: Date (DD/MM/CCYY), Field Length: 10

Dataset

Date MYC Testing Reported [DLBCL/Burkitts Lymphoma] Definition: Amend “This date MYC testing was reported” to “The date MTC testing was reported”


Date BCL2/6 Testing Reported – add new data item – implement from 1 October 2020

Virological Testing (1-3) Notes to User; Amend “Users “Hepatitis B includes core and surface. If either core or surface is recorded as positive this should be coded as 01 Positive” to “Hepatitis B includes core antibody and surface antigen. If both tests are not carried out this should be recorded as 89, Test not done. If both tests are carried out and either core or surface is recorded as positive this should be coded as 01 Positive.”
Date of Virological Testing (1-3) Note to User: Add “If both core antibody and surface antigen tests are not carried out record as test not carried out, i.e Not Applicable 10/10/1900.”

Date Discussed by Specialist MDT [Primary Cutaneous Lymphoma] Note to User: Remove “Required for QPI:10”

Treatment Intent Note to User: Remove “All patients with low grade lymphoma being treated with the intention of reaching durable remission should be recorded as curative for the purposes of QPI reporting.” Codes and Values: Remove Code 2, Palliative. “Any treatment given for the control of symptoms resulting from the cancer e.g. surgery, radiotherapy, or Systemic Anti-Cancer Therapy (SACT)” and add code 5, Non-curative: “Any treatment given for the control of symptoms resulting from the cancer e.g. surgery, radiotherapy, or Systemic Anti-Cancer Therapy (SACT). This includes low grade lymphoma being treated with the intention of reaching durable remission.”

Date of Issue of Pathology Report {Lymphoma} – add new data item – implement from 1 October 2020

Morphology of Tumour {Lymphoma} Note for Users Amend: Required for QPI(s): “1-13” to “1-5, 7-9, 11”

Cotswold Clinical Stage {Lymphoma} Notes for Users Amend: Required QPI: “8(archived), 9(archived),12” to “12”

B symptoms {Lymphoma} Notes for Users Amend: Required QPI: “8(archived), 9(archived),12” to “12”

Bulk Disease Notes for Users Amend: Required QPI: “8(archived), 12” to “12”

Radiotherapy {Lymphoma} Notes for Users Remove: “Required QPI: 8(archived), 9(archived)”

Type of Systemic Anti-Cancer Therapy (SACT) Notes for Users Amend: Required QPI: “2,6,7(archived), 8(archived), 9(archived),11, 13” to “2,11”

Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT) Notes for Users Remove: “Required QPI: 8”

Anti-B Cell Monoclonal Antibody Therapy {Lymphoma} Notes for Users: Remove “Required for QPI: 6”

Rituximab + CHOP {Lymphoma} Notes for Users: Remove “Required for QPI: 7(archived)”

BEACOPP/BEACOPDac Chemotherapy {Lymphoma} – add new Data Item - Implement from 1 October 2020
Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer}
Note for Users: Remove “Required for QPI:2”.
Related Data Items: Add “Date Started Systemic Anti-Cancer Therapy (SACT)”

Date of Final Systemic Anti-Cancer Therapy (SACT) Treatment – add new data item – implement from 1 October 2020

Date Started Cycle 2 ABVD/BEACOPP/BEACOPDac Chemotherapy {Lymphoma} Amend Data Item from “Date Started Cycle 2 ABVD Chemotherapy {Lymphoma}” to “Date Started Cycle 2 ABVD/BEACOPP/BEACOPDac Chemotherapy {Lymphoma}”
Definition: Add “or BEACOPP or BEACOPDac”
Note to User: Amend: “This is the first dose of the second cycle of a course of ABVD chemotherapy. Note this type of chemotherapy is used specifically to treat Hodgkin Lymphoma. If the date of the second cycle of ABVD is unknown, record as 09/09/1900. If the patient has not undergone ABVD chemotherapy, record as not applicable, 10/10/1900.” to “This is the first dose of the second cycle of a course of ABVD or BEACOPP or BEACOPDac chemotherapy. Note these types of chemotherapy are used specifically to treat Hodgkin Lymphoma. If the date of the second cycle of ABVD/BEACOPP/BEACOPDac is unknown, record as 09/09/1900. If the patient has not undergone ABVD/BEACOPP/BEACOPDac chemotherapy, record as not applicable, 10/10/1900.”

Date of Interim PET CT Scan {Lymphoma} Definition: Add “or BEACOPP or BEACOPDac”
Notes for Users: Add “or BEACOPP or BEACOPDac” and “If the patient dies during treatment record as 08/08/1900”

Date Interim PET CT Scan Reported. Definition: Add “or BEACOPP or BEACOPDac”
Note for Users: Add “or BEACOPP or BEACOPDac”

Maintenance Therapy {Lymphoma} Notes for Users: Remove “Required for QPI:13”

Date of Radiological Imaging Post Treatment Completed {Lymphoma}. Note for users: Amend “classified” to “calculated within the measurability”

Patient Entered Into Clinical Trial {Lymphoma} Note for Users: Remove “Required for QPI 6, 7(archived), 8(archived), 9(archived), 13”

Date of Death Note for Users. Amend “Required for QPI(s):4,7,10” to “Required for QPI(s): 4, 7 and for survival analysis.”

Morphology of Tumour {Lymphoma} Code and Values Table: Amend “97173A – Intestinal T-Cell Lymphoma” to “97173C – Intestinal T-Cell Lymphoma”

Date of Referral Notes for users updates to include table for guidance.
Revisions to Data set outwith review and rebranding Updates (February 2021)

Key Information - Author amended from Information Services Division (ISD) to Public Health Scotland (PHS)

Dataset

Abti-B Cell Monoclonal Antibody Therapy {Lymphoma} (ANTIBCELL): Notes for Users add ‘e.g. NA where SACT is not given and NO when SACT is given but it is not rituximab’

Rituximab + CHOP {Lymphoma}: Codes and Values table add code ‘96’, ‘Not Applicable’

Morphology of Tumour {Lymphoma} – Lymphoma Morphology Codes
Create ‘Uncertain if B or T Cell’ Table and add:‘95913’, ‘Malignant Lymphoma, Non-Hodgkin, Not Otherwise Specified’
Hodgkin Lymphomas Table amend: ‘96503’, ‘Classic Hodgkin Lymphoma’ to ‘96503’, ‘Classic Hodgkin Lymphoma (incl PTLD)’
Immunodeficiency-Associated Lymphoproliferative Disorders Table removed: ‘96503’, ‘Classic Hodgkin Lymphoma PTLD’

Addition to dataset during COVID 19 Pandemic (August 2020)

Database Specification

Date of Referral - add new Data item, Field Name: REFERDATE, Field Type: Date (DD/MM/CCYY), Field Length: 10

COVID 19 impact - add new Data item, Field Name: COVID, Field Type: Integer, Field Length: 2

Dataset

Date of Referral - add new data item - implement from 1 March 2020

COVID 19 impact - add new Data item – implemented from 1 October 2019

Revisions to Dataset Outwith Review (August 2020)

Person Sex at Birth – Codes and Values table remove leading ‘0’

Radiological Staging Investigations complete (Lymphoma) – Codes and Values table remove leading ‘0’

FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) – Codes and Values table remove leading ‘0’
Virological Testing (1-3) – Codes and Values table remove leading ‘0’
Type of First Cancer Treatment – Codes and Values table remove leading ‘0’
Treatment Intent – Codes and Values table remove leading ‘0’
Number of Nodal Sites {Lymphoma} – Codes and Values table remove leading ‘0’
Number of Extranodal Sites {Lymphoma} – Codes and Values table remove leading ‘0’
Serum LDH – Codes and Values table remove leading ‘0’
IPI (Lymphoma) – Codes and Values table remove leading ‘0’
FLIPI (Lymphoma) – Codes and Values table remove leading ‘0’
Cotswold Clinical Stage(Lymphoma) – Codes and Values table remove leading ‘0’
B Symptoms (Lymphoma) – Codes and Values table remove leading ‘0’
Manchester Stage {Lymphoma} – Codes and Values table remove leading ‘0’
Bulk Disease – Codes and Values table remove leading ‘0’
Radiotherapy {Lymphoma} – Codes and Values table remove leading ‘0’
Type of Systemic Anti-Cancer Therapy (SACT) (1-3) – Codes and Values table remove leading ‘0’
Abti-B Cell Monoclonal Antibody Therapy {Lymphoma} – Codes and Values table remove leading ‘0’
R-CHOP {Lymphoma} – Codes and Values table remove leading ‘0’
ABVD Chemotherapy {Lymphoma} – Codes and Values table remove leading ‘0’
Maintenance Therapy {Lymphoma} – Codes and Values table remove leading ‘0’
Bone Marrow Transplant – Codes and Values table remove leading ‘0’
Follow-up Status – Codes and Values table remove leading ‘0’
Trasformation to High Grade – Codes and Values table remove leading ‘0’

Update to Dataset due to WHO4 classification implemented from 1 October 2019
Morphology of tumour (Lymphoma) Main Source of Data Item Standard amend to 'WHO Histological Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition). Codes and Values table updated

Revisions to Dataset outwith Review (October 2019)

Database Specification

Date Started Cycle 3 ABVD Chemotherapy {Lymphoma} - Archive data item

Date Started Cycle 3 Chemotherapy {Lymphoma} – Add new data item Field Name CHEMDATE3, Field Type: Date (DD/MM/CCYY), Field Length 10

Dataset

Date Radiological Staging Investigations Completed {Lymphoma} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date of Radiology Request - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’, amend ‘If more than one CT scan undertaken the final CT scan date should be recorded to align with the date of the investigation.” to ‘If more than one CT scan is undertaken, the request date for the final scan should be recorded.’

Date Radiological Staging Investigations Reported - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date of Radiology Request for FDG-PET/CT (PET/CT0 Scan {Lymphoma} (Pre-treatment) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date of Integrated FDG-PET/CT (PET/CT) Scan Reported - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date MYC Testing Reported [DLBCL/Burkitts Lymphoma] - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Diagnosis {Cancer} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’

Date of Virological Testing (1-3) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Discussed by Haematology Care Team (MDT) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’
Date Discussed by Specialist MDT [Primary Cutaneous Lymphoma] - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date of First Cancer Treatment {Lymphoma} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Treatment Started {Cancer} (Radiotherapy) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Treatment Completed {Cancer} (Radiotherapy) - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Started Cycle 2 ABVD Chemotherapy {Lymphoma} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Started Cycle 3 ABVD Chemotherapy {Lymphoma} - Archive data item

Date Started Cycle 3 Chemotherapy {Lymphoma} – Add new data item

Date of Interim PET CT Scan {Lymphoma} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date Interim PET CT Scan Reported - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Maintenance Therapy {Lymphoma} – Codes and Values table add code ‘94’, ‘Patient died before treatment’

Date of radiological Imaging Port Treatment Completed {Lymphoma} - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’, ‘10/10/1010’ to ‘10/10/1900’ and ‘08/08/0808’ to ‘08/08/1900’

Post-Treatment Assessment Date - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Follow-up Date/Date of Relapse/Progression - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Date of Death - Notes for Users amend ‘09/09/0909’ to ‘09/09/1900’ and ‘10/10/1010’ to ‘10/10/1900’

Revisions to Dataset outwith Review (December 2018)
**Criteria for Inclusion of Patients in Audit** - Exclude ‘any lymphoma transformed from a low grade lymphoma” and not just specifically DLBCL’

**Date of Radiological Imaging Post Treatment Completed** - Notes for Users amend ‘If patient dies during treatment record as 08/08/1900’ to ‘Patients who have not finished treatment or if patient dies during treatment record as 08/08/1900’

---

**Revisions to Dataset at Formal Review (December 2017)**

**Criteria for Inclusion of Patients in Audit** – Exclude Add Patients with Small B-cell Lymphocytic Lymphoma (SLL)

**Database Specification**

Date Radiological Staging Investigations Reported - Add new data item Field Name: RADREPORTDATE, Field Type: Date (DD/MM/CCYY), Field Length 10.

**Date Integrated FDG-PET/CT(PET/CT) Scan Reported** - Add new data item Field Name: PETREPORTDATE, Field Type: Date (DD/MM/CCYY), Field Length 10

Rituximab {Lymphoma} – **Remove Data Item**

Anti-B Cell Monoclonal Antibody Therapy {Lymphoma} – **Add new Data Item** Field Name: ANTIBCELL

ABVD Chemotherapy {Lymphoma} - Add new data item Field Name: ABVD, Field Type: Integer, Field Length 2

**Date Started Cycle 2 ABVD Chemotherapy {Lymphoma}** - Add new data item Field Name: ABVDDATE2, Field Type: Date (DD/MM/CCYY), Field Length 10

**Date Started Cycle 3 ABVD Chemotherapy {Lymphoma}** - Add new data item Field Name: ABVDDATE3, Field Type: Date (DD/MM/CCYY), Field Length 10

**Date of Interim PET CT Scan {Lymphoma}** - Add new data item Field Name: ABVDPETDATE, Field Type: Date (DD/MM/CCYY), Field Length 10

**Date Interim PET CT Scan Reported** - Add new data item Field Name: ABVDREPORTDATE, Field Type: Date (DD/MM/CCYY), Field Length 10

Maintenance Therapy {Lymphoma} - Add new data item Field Name: MAINT, Field Type: Integer, Field Length 2

**Dataset**
**Date of First Cancer Treatment** - Notes for Users add ‘Where this has subsequently been confirmed at MDT, the date of MDT should be recorded.’

Date of First Cancer Treatment {Lymphoma} - Notes for Users add ‘Required for QPI (s): 1, 3’

Virological Testing (1-3) - Notes for Users add ‘If either core or surface is recorded as positive this should be coded as 01 Positive.’ explanatory note for code 96

Not applicable change from ‘rituximab treatment’ to ‘SACT’

**Date of First Cancer Treatment {Lymphoma}** - Notes for Users add ‘Required for QPI (s): 1, 3’

Morphology of Tumour {Lymphoma} Notes for Users amend ‘Required for QPI(s): 1-11 to 1-13. Codes and Values table delete ‘Code 98233, Small B-cell Lymphocytic Lymphoma, is also utilised for CLL. However patients with CLL should not be recorded in this dataset.’ Delete in Lymphoma Morphology Codes ‘98233 Small B-cell Lymphocytic Lymphoma’.

**Cotswold Clinical Stage {Lymphoma}** - Notes for Users add ‘Required for QPI: 12’

**B Symptoms {Lymphoma}** - Notes for Users add ‘Required for QPI: 12’

**Bulk Disease** - Notes for Users add ‘Required for QPI: 12’

**Radiotherapy {Lymphoma}** - Notes for Users delete ‘Required for QPI: 5’

Type of Systemic Anti-Cancer Therapy (SACT) - Notes for Users add ‘Required for QPI (s): 11, 13’ delete QPI: 5. Codes and Values table delete ‘Code 3 – Maintenance Immunotherapy’. Notes for Users remove ‘Follicular Lymphoma only: rituximab for 2 years post chemotherapy. Maintenance immunotherapy occurs immediately after chemotherapy for a period of up to 2 years. At present Rituximab is the only immunotherapy agent which will be given in this indication.’

**Rituximab {Lymphoma}** - **Remove Data Item**

Anti-B Cell Monoclonal Antibody Therapy {Lymphoma} – Add new Data Item

**Rituximab + CHOP {Lymphoma}** - Notes for Users delete ‘Required for QPI (s): 6, 11’

**Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer}** - Notes for Users delete ‘Up to three courses may be recorded.’

**ABVD Chemotherapy {Lymphoma}** - Add new data item.
Date Started Cycle 2 ABVD Chemotherapy {Lymphoma} - Add new data item.

Date Started Cycle 3 ABVD Chemotherapy {Lymphoma} - Add new data item

Date of Interim PET CT Scan {Lymphoma} - Add new data item.

Date Interim PET CT Scan Reported - Add new data item

Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer} - Notes for Users delete ‘Required for QPI: 5’

Maintenance Therapy {Lymphoma} - Add new data item.

Patient Entered into Clinical Trial {Lymphoma} - Notes for Users add ‘Required for QPI: 13’

Revisions to Dataset following Baseline Review (January 2016)

Database Specification:

WBC Differential Lymphocytes – Field Length amend to 6 field type numbers (nnnn.nn)

Dataset

Radiological Staging Investigations Complete {Lymphoma} - Notes for Users add ‘Separate codes to identify complete CT scans with / without CT neck are required to inform clinical debate.’

Date Radiological Staging Investigations Completed {Lymphoma} - Definition, delete ‘of the chest, abdomen and pelvis ± neck’. Notes for users delete ‘Complete staging is CT of chest, abdomen and pelvis ± neck (and no other combination).’

FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) - Definition, delete ‘of Hodgkin Lymphoma’. Notes for Users add Required for QPI (s): 1, 3

Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) - Notes for Users Add Required for QPI (s): 1, 3

Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) - Notes for Users add Required for QPI (s): 1, 3. Notes for Users, delete ‘or patient has None Hodgkin Lymphoma,’

Virological Testing (1-3) - Notes for Users add ‘virological tests recorded should be those undertaken as part of the diagnostic process.’
Treatment Intent - Notes for Users add Required for QPI (s): 1, 2, 3, 4

Morphology of Tumour {Lymphoma} - Notes for Users add ‘Code 98233, Small B-cell Lymphocytic Lymphoma, is also utilised for CLL. However patients with CLL should not be recorded in this dataset.’ Codes and Values table delete Morphology Code 97613D – WaldenstrOm Macroglobulinaemia and amend code for Lymphoplasmacytic Lymphoma from 96713C to 96713. Add 98233 – Small B-cell Lymphocytic Lymphoma.

WBC Differential Lymphocytes - Field length 6 field type numbers (nnn.nn), change to 999.99 (Not recorded).

IPI {Lymphoma} - Notes for Users add ‘All Hodgkin lymphoma patients, or those with known distant metastasis who would not require this prognostic index calculated code as Not applicable’ and Non - Hodgkin lymphoma with known distant metastasis or where not recorded in clinical notes code as Not known.

Location Code {Oncology Treatment} - Notes for Users replace last paragraph. With ‘If oncological treatment has not been performed or the patient has refused, record the hospital where clinic was attended.

Radiotherapy {Lymphoma} - Notes for Users add ‘Treatment received for initial management and not treatment of recurrence or relapse. If the patients type of first treatment was ‘supportive care only’ or ‘watchful waiting’ then subsequently proceeds to active treatment at a later date, only record if treatment occurs within 6 months of diagnosis.’

Date Treatment Completed {Cancer} (Radiotherapy) - Notes for Users add ‘Required for QPI: 2.’

Type of Systemic Anti-Cancer Therapy (SACT) (1-3) - Notes for Users add ‘Treatment received for initial management and not treatment of recurrence or relapse. If the patients type of first treatment was ‘supportive care only’ or ‘watchful waiting’ then subsequently proceeds to active treatment at a later date, only record if treatment occurs within 6 months of diagnosis.’

Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT) - Notes for Users delete as follows ‘Required for QPI(s): 2, 8

Date of Radiological Imaging Post Treatment Completed {Lymphoma} - Definition add ‘or PET CT’ in Notes for Users add ‘or PET CT.’ At end of Notes for Users add paragraph. ‘If patient dies during treatment record as 08/08/1900.’

Revisions to Dataset outwith Review (February 2015)

Database Specification

Virological Testing (1-3) – Field Name changed HEPC

Date of First Cancer Treatment - Change to Date (DD/MM/CCYY)
Haemoglobin - Field name change to HAEMOGLOB

Total Number of Systemic Anti-Cancer Therapy Cycles Planned (SACT) – Field Length change to 4

Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT) - Field name change to SACTCYC1

Dataset

FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment) - Codes and Values table add ‘99’ (Not recorded)

MYC Testing Result [DLBCL/Burkitts Lymphoma – Codes and Values table add ‘99’ (Not recorded)

Virological Testing (1-3) – Codes And Values table add ‘99’ (Not recorded)

WHO/ ECOG Performance Status – Codes and Values table add ‘99’ (Not recorded)

Rituximab {Lymphoma} – Codes and Values table add ‘99’ (Not recorded)

Rituximab + CHOP {Lymphoma} – Codes and Values table add ‘99’ (Not recorded)

Follow-up Status - Codes and Values table add ‘99’ (Not recorded)

WBC Total - Field Length amend to 5

WBC Differential Lymphocytes – Field Length amend field length 5

Revisions to Dataset at 9 Month Review (September 2014)

Database Specification

Type of First Cancer Treatment {Lymphoma} – Add new Data Item Field Name: FIRSTTREATTYPE, Field Type: Integer, Field Length 2.

Date of First Cancer Treatment {Lymphoma} – Add new Data Item Field Name: FIRSTTREATDATE, Field Type: Date, Field Length: 10.

Dataset:

Radiological Staging Investigations Complete {Lymphoma} – Codes and Values table Explanatory notes add code ‘96’ – patient not for treatment or further investigation.
MYC Testing Result [DLBCL/Burkitts Lymphoma] - Codes and Values table add the code '03' failed and code '04' indeterminate, Add to explanatory notes for negative – 'normal' and for positive – 'rearranged'.

Location of Diagnosis {Cancer} - Notes for Users add 'Must be a valid hospital code listed in the national reference file and if location is unknown record as X9999'

Treatment intent - Notes for Users add 'all patient with low grade Lymphoma being treated with the intention of reaching durable remission should be recorded as curative for the purposes of QPI reporting'

Type of First Cancer Treatment {Lymphoma} – Add new Data Item

Date of First Cancer Treatment {Lymphoma} - Add new Data item

Morphology of Tumour {Lymphoma} - Codes and Values table remove codes 1111/1 and 8888/8

Number of Nodal Sites {Lymphoma} - Notes for Users add Number Nodal Sites should be stated by Clinician/MDT record as ‘99’ if not recorded.

Number of Extranodal Sites {Lymphoma} - Notes for Users add Number Extranodal Sites should be stated by Clinician/MDT record as ‘99’ if not recorded.

Serum LDH - Notes for Users add Record the last available result prior to starting treatment.

WBC Total - Delete code 1010 (not known), Amend code 9999 (not recorded) to code 999.9

WBC Differential – Notes for Users delete code 1010 (not known), Amend code 9999 (not recorded) to code 99.99

IPI {Lymphoma} - Notes for Users add ‘If result is unclear please seek clarification from Clinician’

FLIPI {Lymphoma} - Notes for Users add ‘If result is unclear please seek clarification from Clinician’

B Symptoms {Lymphoma} – Codes and Values table remove code ‘96’ – not applicable

Radiotherapy {Lymphoma} – Codes and Values table Remove code ‘96’ – not applicable

Type of Systemic Anti-Cancer Therapy (SACT) (1-3) - Field Name remove SACT2 and SACT3

Total Number of Systemic Anti-Cancer Therapy Cycles Planned (SACT) (1-3) - Field Name remove PLSACTCYC2 and PLSACTCYC3
Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT) (1-3) – Field Name remove SACTCYC2 and SACTCYC3

Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer} (1-3) - Field Name remove SACTDATE2 and SACTDATE3

Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} (1-3) - Field Name remove SACTENDATE2 and SACTENDATE3

Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer} 1-3 – Noyes for Users amend from ‘This is the last dose of the last cycle of a course of chemotherapy or immunotherapy e.g. day 1 of final cycle should be recorded, the date the final treatment was actually delivered to the patient, irrespective if this was planned completion or not.’ to ‘This is the first day of the last cycle of a course of SACT’.

Revisions to Dataset outwith Review (June 2014)

Dataset

Systemic Therapy Agent {Lymphoma} (1-3) - Remove Data Item

Patient Entered into clinical Trial {Lymphoma} – Codes and Values table amended code ‘96’ - Not applicable and added code ‘95’ – Patient refused clinical trial.

WBC Total - Field Type amended to number. (nnn.n)

WBC Differential - Field Type amended to number (nn.nn)

Radiotherapy {Lymphoma} - Codes and Values table explanatory notes remove against ‘Code 96 not applicable’ – No radiotherapy given

Type of Systemic Anti-Cancer Therapy (SACT) (1-3) - Codes and Values table Add code ‘06’ - Single Agent Immunotherapy.

Rituximab {Lymphoma} - Add New Data Item

R-CHOP {Lymphoma} - Add New Data Item
CRITERIA FOR INCLUSION OF PATIENTS IN AUDIT

To facilitate national comparisons the same patients must be audited throughout Scotland. It is therefore important to document the patient eligibility criteria for each national cancer audit data set.

Include:
- All patients with a confirmed new primary lymphoma (see page 32 for morphology inclusion codes)
- Including all patients who have had a previous primary malignancy of any site or a concurrent primary malignancy of another site.

Exclude:
- Patients with Small B-cell Lymphocytic Lymphoma (SLL)
- Patients with recurrent disease (as opposed to a new primary) including patients with DLBCL transformed from low grade disorders.
- Patients, at date of diagnosis, under 16 years of age i.e. up to 15 years 364 days.
- Patients where the only record of their cancer is from a death certificate (DCO).
- Patients with normal residence outwith Scotland.
- Patients whose definitive cancer treatment was privately funded or undertaken outwith NHS Scotland.
- Any lymphoma transformed from a low grade lymphoma and not just specifically DLBCL
DATABASE SPECIFICATION

DOWNLOAD FORMAT

To assist with downloading data to PHS for the National Quality Assurance Programme and other agreed activities, all sites should be able export data according to the following specification.

<table>
<thead>
<tr>
<th>Data Item</th>
<th>Field Name</th>
<th>Field Type</th>
<th>Size</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Section 1: Demographic Items</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Person Family Name</td>
<td>PATSNAME</td>
<td>Characters</td>
<td>35</td>
<td>2</td>
</tr>
<tr>
<td>Person Given Name</td>
<td>PATFNAME</td>
<td>Characters</td>
<td>35</td>
<td>3</td>
</tr>
<tr>
<td>Patient Postcode at Diagnosis {Cancer}</td>
<td>PATPCODE</td>
<td>Characters</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Date of Birth</td>
<td>DOB</td>
<td>Date</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Person Sex at Birth</td>
<td>SEX</td>
<td>Integer</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>CHI Number</td>
<td>CHINUM</td>
<td>Characters</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td><strong>Section 2: Pre-treatment Imaging and Staging Investigations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Referral</td>
<td>REFERDATE</td>
<td>Date</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Radiological Staging Investigations Complete {Lymphoma}</td>
<td>SINVEST</td>
<td>Integer</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>Date Radiological Staging Investigations Completed {Lymphoma}</td>
<td>SINVESTDATE</td>
<td>Date</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>Date of Radiology Request</td>
<td>RADREQDATE</td>
<td>Date</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Date Radiological Staging Investigations Reported</td>
<td>RADREPORTDATE</td>
<td>Date</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)</td>
<td>PETSCAN</td>
<td>Integer</td>
<td>2</td>
<td>15</td>
</tr>
<tr>
<td>Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)</td>
<td>PETREQDATE</td>
<td>Date</td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td>Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)</td>
<td>PETDATE</td>
<td>Date</td>
<td>10</td>
<td>17</td>
</tr>
<tr>
<td>Date Integrated FDG-PET/CT (PET/CT) Scan Reported</td>
<td>PETREPORTDATE</td>
<td>Date</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>Date MYC Testing Reported [DLBCL/Burkitts Lymphoma]</td>
<td>MYCDATE</td>
<td>Date</td>
<td>10</td>
<td>19</td>
</tr>
<tr>
<td>MYC Testing Result [DLBCL/Burkitts Lymphoma]</td>
<td>MYCRESULT</td>
<td>Integer</td>
<td>2</td>
<td>20</td>
</tr>
<tr>
<td>Date BCL2/6 Testing Reported</td>
<td>BCLDATE</td>
<td>Date</td>
<td>10</td>
<td>21</td>
</tr>
<tr>
<td>Location of Diagnosis {Cancer}</td>
<td>HOSP</td>
<td>Characters</td>
<td>5</td>
<td>22</td>
</tr>
<tr>
<td>Data Item</td>
<td>Field Name</td>
<td>Field Type</td>
<td>Size</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------</td>
<td>--------------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Date of Diagnosis {Cancer}</td>
<td>DIAGDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>23</td>
</tr>
<tr>
<td>Virological Testing (1-3)</td>
<td>HEPB</td>
<td>Integer</td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Virological Testing (1-3)</td>
<td>HEPC</td>
<td>Integer</td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Virological Testing (1-3)</td>
<td>HIV</td>
<td>Integer</td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Date of Virological Testing (1-3)</td>
<td>HEPBDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>26</td>
</tr>
<tr>
<td>Date of Virological Testing (1-3)</td>
<td>HEPCDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>26</td>
</tr>
<tr>
<td>Date of Virological Testing (1-3)</td>
<td>HIVDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>26</td>
</tr>
<tr>
<td>Date Discussed by Haematology Care Team (MDT)</td>
<td>MDTDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>27</td>
</tr>
<tr>
<td>Date Discussed by Specialist MDT [Primary Cutaneous Lymphoma]</td>
<td>SPECMDTDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>28</td>
</tr>
<tr>
<td>COVID 19 Impact</td>
<td>COVID</td>
<td>Integer</td>
<td>2</td>
<td>29</td>
</tr>
<tr>
<td>WHO/ ECOG Performance Status</td>
<td>PSTATUS</td>
<td>Integer</td>
<td>1</td>
<td>30</td>
</tr>
<tr>
<td>Treatment Intent</td>
<td>INTENT</td>
<td>Integer</td>
<td>2</td>
<td>31</td>
</tr>
<tr>
<td>Type of First Cancer Treatment</td>
<td>FIRSTTREATTYPE</td>
<td>Integer</td>
<td>2</td>
<td>32</td>
</tr>
<tr>
<td>Date of First Cancer Treatment</td>
<td>FIRSTTREATDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>33</td>
</tr>
</tbody>
</table>

**Section 3: Pathology**

<table>
<thead>
<tr>
<th>Data Item</th>
<th>Field Name</th>
<th>Field Type</th>
<th>Size</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Issue of Pathology Report {Lymphoma}</td>
<td>DPATHREP</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>35</td>
</tr>
<tr>
<td>Morphology of Tumour {Lymphoma}</td>
<td>MORPHOL</td>
<td>Characters</td>
<td>6</td>
<td>36</td>
</tr>
<tr>
<td>Number of Nodal Sites {Lymphoma}</td>
<td>NONODAL</td>
<td>Integer</td>
<td>2</td>
<td>39</td>
</tr>
<tr>
<td>Number of Extranodal Sites {Lymphoma}</td>
<td>EXNODAL</td>
<td>Integer</td>
<td>2</td>
<td>40</td>
</tr>
<tr>
<td>Serum LDH</td>
<td>SERLDH</td>
<td>Integer</td>
<td>2</td>
<td>41</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>HAEMOGLOB</td>
<td>Integer</td>
<td>4</td>
<td>42</td>
</tr>
<tr>
<td>Albumin at Diagnosis</td>
<td>ALBUMIN</td>
<td>Integer</td>
<td>4</td>
<td>43</td>
</tr>
<tr>
<td>WBC Total</td>
<td>WBCTOT</td>
<td>Number</td>
<td>5</td>
<td>44</td>
</tr>
<tr>
<td>WBC Differential – Lymphocytes</td>
<td>WBCLYMPHO</td>
<td>Number (nnn.nn)</td>
<td>6</td>
<td>45</td>
</tr>
</tbody>
</table>

**Section 4: Classification**

<table>
<thead>
<tr>
<th>Data Item</th>
<th>Field Name</th>
<th>Field Type</th>
<th>Size</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPI {Lymphoma}</td>
<td>IPI</td>
<td>Integer</td>
<td>2</td>
<td>47</td>
</tr>
<tr>
<td>FLIPI {Lymphoma}</td>
<td>FLIPI</td>
<td>Integer</td>
<td>2</td>
<td>48</td>
</tr>
<tr>
<td>Hasenclever Index for Hodgkin Disease {Lymphoma}</td>
<td>HASENINDEX</td>
<td>Integer</td>
<td>2</td>
<td>49</td>
</tr>
<tr>
<td>Cotswold Clinical Stage {Lymphoma}</td>
<td>COTSWOLD</td>
<td>Integer</td>
<td>2</td>
<td>50</td>
</tr>
<tr>
<td>B Symptoms {Lymphoma}</td>
<td>BSYMPTOM</td>
<td>Integer</td>
<td>2</td>
<td>51</td>
</tr>
<tr>
<td>Manchester Stage {Lymphoma}</td>
<td>MANCHESTER</td>
<td>Integer</td>
<td>2</td>
<td>52</td>
</tr>
<tr>
<td>Bulk Disease</td>
<td>BULKDISEASE</td>
<td>Integer</td>
<td>2</td>
<td>53</td>
</tr>
</tbody>
</table>

**Section 5: Oncology Treatment**

Data Definitions for the National Minimum Core Dataset for Lymphoma.
Developed by ISD Scotland, 2013
Page xix
<table>
<thead>
<tr>
<th>Data Item</th>
<th>Field Name</th>
<th>Field Type</th>
<th>Size</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location Code {Oncology Treatment}</td>
<td>HOSPNONSURG</td>
<td>Characters</td>
<td>5</td>
<td>55</td>
</tr>
<tr>
<td>Radiotherapy {Lymphoma}</td>
<td>RADIOTYPE1</td>
<td>Integer</td>
<td>2</td>
<td>56</td>
</tr>
<tr>
<td>Date Treatment Started {Cancer} (Radiotherapy)</td>
<td>RSRTDATE1</td>
<td>Date</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>Date Treatment Completed {Cancer} (Radiotherapy)</td>
<td>RCOMPDATE1</td>
<td>Date</td>
<td>10</td>
<td>58</td>
</tr>
<tr>
<td>Type of Systemic Anti-Cancer Therapy (SACT)</td>
<td>SACT1</td>
<td>Integer</td>
<td>2</td>
<td>59</td>
</tr>
<tr>
<td>Total Number of Systemic Anti-Cancer Therapy Cycles Planned (SACT)</td>
<td>PLSACTCYC1</td>
<td>Integer</td>
<td>4</td>
<td>60</td>
</tr>
<tr>
<td>Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT)</td>
<td>SACTCYC1</td>
<td>Integer</td>
<td>4</td>
<td>61</td>
</tr>
<tr>
<td>Anti-B Cell Monoclonal Antibody Therapy {Lymphoma}</td>
<td>ANTIBCELL</td>
<td>Integer</td>
<td>2</td>
<td>62</td>
</tr>
<tr>
<td>Rituximab + CHOP {Lymphoma}</td>
<td>RCHOP</td>
<td>Integer</td>
<td>2</td>
<td>64</td>
</tr>
<tr>
<td>ABVD Chemotherapy {Lymphoma}</td>
<td>ABVD</td>
<td>Integer</td>
<td>2</td>
<td>65</td>
</tr>
<tr>
<td>BEACOPP/BEACOPDac Chemotherapy</td>
<td>BEACOPP</td>
<td>Integer</td>
<td>2</td>
<td>66</td>
</tr>
<tr>
<td>Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer}</td>
<td>SACTDATE1</td>
<td>Date</td>
<td>10</td>
<td>67</td>
</tr>
<tr>
<td>Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer}</td>
<td>SACTENDATE1</td>
<td>Date</td>
<td>10</td>
<td>68</td>
</tr>
<tr>
<td>Date of Final Systemic Anti-Cancer Therapy (SACT) Treatment</td>
<td>SACTFINALDATE1</td>
<td>Date</td>
<td>10</td>
<td>69</td>
</tr>
<tr>
<td>Date Started Cycle 2 ABVD/BEACOPP/BEACOPD Chemotherapy {Lymphoma}</td>
<td>ABVDDATE2</td>
<td>Date</td>
<td>10</td>
<td>70</td>
</tr>
<tr>
<td>Date Started Cycle 3 Chemotherapy {Lymphoma}</td>
<td>CHEMDATE3</td>
<td>Date</td>
<td>10</td>
<td>71</td>
</tr>
<tr>
<td>Date of Interim PET CT Scan {Lymphoma}</td>
<td>ABVDPETDATE</td>
<td>Date</td>
<td>10</td>
<td>72</td>
</tr>
<tr>
<td>Date Interim PET CT Scan Reported</td>
<td>ABVDREPORTDATE</td>
<td>Date</td>
<td>10</td>
<td>73</td>
</tr>
<tr>
<td>Maintenance Therapy {Lymphoma}</td>
<td>MAINT</td>
<td>Integer</td>
<td>2</td>
<td>74</td>
</tr>
<tr>
<td>Bone Marrow Transplant</td>
<td>BONETR</td>
<td>Integer</td>
<td>2</td>
<td>75</td>
</tr>
<tr>
<td>Date of Radiological Imaging Post Treatment Completed {Lymphoma}</td>
<td>POSTIMAGDATE</td>
<td>Date</td>
<td>10</td>
<td>76</td>
</tr>
</tbody>
</table>

**Section 6: Clinical Trial Entry**

| Patient Entered into Clinical Trial {Lymphoma} | TRIAL | Integer | 2 | 78 |

**Section 7: Follow-up**
<table>
<thead>
<tr>
<th>Data Item</th>
<th>Field Name</th>
<th>Field Type</th>
<th>Size</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response Post First Treatment</td>
<td>FTRESPONS</td>
<td>Integer</td>
<td>2</td>
<td>80</td>
</tr>
<tr>
<td>Post-Treatment Assessment Date</td>
<td>POSTTREATDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>81</td>
</tr>
<tr>
<td>Follow-up Status</td>
<td>FUSTATUS</td>
<td>Integer</td>
<td>2</td>
<td>82</td>
</tr>
<tr>
<td>Follow-up Date/Date of Relapse/Progression</td>
<td>FUDATE</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>83</td>
</tr>
<tr>
<td>Transformation to High Grade</td>
<td>TRANS</td>
<td>Integer</td>
<td>2</td>
<td>84</td>
</tr>
<tr>
<td><strong>Section 8: Death Details</strong></td>
<td></td>
<td></td>
<td></td>
<td>85</td>
</tr>
<tr>
<td>Date of Death</td>
<td>DOD</td>
<td>Date (DD/MM/CCYY)</td>
<td>10</td>
<td>86</td>
</tr>
</tbody>
</table>
Section 1: Demographic Items
Person Family Name

Common Name(s): Surname, Family name

Main Source of Data Item Standard: Government Data Standards Catalogue

Definition:
That part of a person's name which is used to describe family, clan, tribal group, or marital association at the time of diagnosis.

Field Name: PATSNAME
Field Type: Characters
Field Length: 35

Notes for Users:
The surname of a person represents that part of the name of a person indicating the family group of which the person is part.

It should be noted that in Western culture this is normally the latter part of the name of a person. However, this is not necessarily true of all cultures. This will, of course, give rise to some problems in the representation of the name. This is resolved by including the data item Name Element Position in the structured name indicating the order of the name elements.

From SMR Definitions and Codes

Codes and Values:

Related Data Items:
Person Given Name

Common Name(s): Forename, Given Name, Personal Name

Main Source of Data Item Standard: Government Data Standards Catalogue

Definition:
The forename or given name of a person.

Field Name: PATFNAME
Field Type: Characters
Field Length: 35

Notes for Users:
The first forename of a person represents that part of the name of a person which after the surname is the principal identifier of a person.

Where the person's preferred forename is not the first forename, the related data item 'Preferred Forename' should be used to indicate this.

Codes and Values:

Related Data Items:
Patient Postcode at Diagnosis {Cancer}

Main Source of Data Item Standard: Government Data Standards Catalogue

Definition:
Postcode of patient's usual place of residence on the date of diagnosis

Field Name: PATPCODE
Field Type: Characters
Field Length: Maximum 8

Notes for Users:
Postcode is included in BS7666 Address (GDSC) but there is also a separate Post Code standard which will be populated from BS7666 Address Post Code.

This item can be derived from the date of diagnosis and patient address at that time

Codes and Values: N/A

Related Data Items:
Date of Diagnosis {Cancer}
Date of Birth

Main Source of Data Item Standard: Government Data Standards Catalogue

Definition:
The date on which a person was born or is officially deemed to have been born, as recorded on the Birth Certificate.

Field Name: DOB
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users:
If the patient's date of birth is recorded differently on different occasions, the most frequently used or latest date should be recorded.

The patient's full date of birth inclusive of the century should be recorded. The format should be DD/MM/CCYY e.g. 01/02/2011.

Codes and Values: N/A

Related Data Items:
CHI Number
Person Sex at Birth

**Common Name(s):** Sex at Birth

**Main Source of Data Item Standard:** Derived from the nearest equivalent Government Data Standards Catalogue standard ‘Person Gender at Registration’

**Definition:** This is a factual statement, as far as is known, about the phenotypic (biological) sex of the person at birth

**Field Name:** SEX
**Field Type:** Integer
**Field Length:** 2

**Notes for Users:**
A person’s sex has clinical implications, both in terms of the individual’s health and the health care provided to them.

In the majority of cases, the phenotypic (biological) sex and genotypic sex are the same and the phenotypic sex is usually easily determined. In a small number of cases, accurate determination of genotype may be required

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Not specified/Indeterminate</td>
<td>Where it has not been possible to determine if the person is male or female at birth, e.g. intersex / hermaphrodite.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Items:**
CHI Number
CHI Number

Main Source of Data Item Standard: Scottish Executive Health Department.

Definition:
The Community Health Index (CHI) is a population register, which is used in Scotland for health care purposes. The CHI number uniquely identifies a person on the index.

Field Name: CHINUM
Field Type: Characters
Field Length: 10

Notes for Users:
The Community Health Index (CHI) is a computer based population index whose main function at present is to support primary care services. CHI contains details of all Scottish residents registered with a General Practitioner and was originally envisaged and implemented as a population-based index to help assess the success of immunisation and screening programmes. It is therefore closely integrated with systems for child health, cervical cytology and breast screening call and recall...It is intended that this number, the Scottish equivalent of the new NHS number in England and Wales, should become the Unique Patient Identifier throughout the NHS in Scotland.

From Designed to Care - Scottish Office

The CHI number is a unique numeric identifier, allocated to each patient on first registration with the system. The CHI number is a 10-character code consisting of the 6-digit date of birth (DDMMYY), two digits, a 9th digit which is always even for females and odd for males and an arithmetical check digit.

(PHS, NHS National Services Scotland)

The CHI number should always be used to identify a patient. However, Health record identifiers, such as hospital numbers in Patient Administration Systems (PAS), may be used locally, in conjunction with the CHI number or in the absence of the CHI number, to track patients and their records.

Although there may be no number when a patient presents for treatment, there must be an allocation at some point in the episode of care as CHI is mandatory on all clinical communications.

Non-Scottish patients and other temporary residents can have a CHI number allocated if required but it is envisaged that future development may allow the identifying number used in other UK countries to be used in Scotland.

Codes and values: N/A

Related Data Items:
Date of Birth
Person Sex at Birth
Section 2: Pre-treatment Imaging and Staging Investigations
Date of Referral

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date on which the patient referral to secondary care for the investigation and / or treatment of Lymphoma cancer was received. If patient is initially seen by a non-haematological specialty for investigation of lymphadenopathy (eg head and neck or general surgery) then the date of the initial GP referral should be recorded and NOT the date the patient was subsequently referred to haematology.

**Field Name:** REFERDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for national survival analysis and national comparative analysis.

See table Overleaf:
<table>
<thead>
<tr>
<th>Referral Mode</th>
<th>Guidance on date of referral</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary care clinician (Dentist, GP, Nurse practitioner)</strong></td>
<td>Record the date on which the patient referral to secondary care for the investigation and / or treatment of cancer was received. If patient is initially seen by a non-haematological specialty for investigation of lymphadenopathy (eg head and neck or general surgery) then the date of the initial GP referral should be recorded and NOT the date the patient was subsequently referred to haematology.</td>
</tr>
<tr>
<td><strong>Screening service</strong></td>
<td>Record the date on which the referral from screening was received by the hospital. If a Screening referrals has not been stamped with the date the referral was received and the exact date cannot be found, the earliest available date should be used.</td>
</tr>
<tr>
<td><strong>Incidental finding / Secondary Care</strong></td>
<td>For patients who are incidentally found or suspected of having a cancer (and a new cancer is subsequently confirmed), the date the patient was referred to a specialist for further investigation and treatment should be used. If no referral is required, the date of the investigation that led to the suspicion of cancer should be used. For example, if a patient was having a mammogram for follow up of a previously diagnosed breast cancer, and a new breast cancer is picked up, an onward referral may not be necessary and the date of the mammogram should be used.</td>
</tr>
<tr>
<td><strong>Review clinic</strong></td>
<td>For patients who attend for routine review either for follow up of a previous cancer (and a new cancer is found) or, patients who attend for follow up for benign disease (and a new cancer is found), the date the patient was referred to a specialist for further investigation and treatment should be used. If no referral is required, the date of the investigation that led to the suspicion of cancer should be used. For example, if a patient was having a mammogram for follow up of a previously diagnosed breast cancer, and a new breast cancer is picked up, an onward referral may not be necessary and the date of the mammogram should be used.</td>
</tr>
<tr>
<td><strong>Cancer genetic clinic</strong></td>
<td>Record the date the referral for the investigation and / or treatment of cancer was received.</td>
</tr>
<tr>
<td><strong>Self-referral to A&amp;E</strong></td>
<td>Record the date the patient self presents to A&amp;E.</td>
</tr>
<tr>
<td><strong>GP referral directly to hospital</strong></td>
<td>Record the date the patient presents to hospital (A&amp;E or other) following referral by their GP (usually the same date as referral).</td>
</tr>
<tr>
<td><strong>Previous GP referral but subsequently admitted to hospital</strong></td>
<td>If the previous GP referral was made due to the same or similar symptoms that led to the patient presenting at A&amp;E, record the date the initial GP referral was received. If the previous referral made by the GP was due to different symptoms, record the patient as self-referral to A&amp;E or GP referral directly to hospital, whichever is appropriate.</td>
</tr>
<tr>
<td><strong>Primary care clinician (dental)</strong></td>
<td>Record the date on which the patient referral to secondary care for the investigation and / or treatment of cancer was received.</td>
</tr>
<tr>
<td><strong>Referral from private healthcare</strong></td>
<td>Record the date on which the patient referral from a private healthcare provider for the investigation and / or treatment of cancer was received by the NHS hospital.</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Record the date on which the patient referral to secondary care for the investigation and / or treatment of cancer was received.</td>
</tr>
<tr>
<td><strong>Not recorded</strong></td>
<td>If the exact date is not documented, record as 09/09/1900.</td>
</tr>
</tbody>
</table>
Radiological Staging Investigations Complete {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by the PHS.

Definition: A record if radiological staging investigations were completed by Computed Tomography (CT) of the chest, abdomen and pelvis ± neck.

Field Name: SINVEST
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI: 1

Staging investigations may be done separately but should be completed.

Complete staging is CT of the chest, abdomen and pelvis ± neck.

Separate codes to identify complete CT scans with / without CT neck are required to inform clinical debate.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Complete – CT Chest, Abdomen and Pelvis</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Complete – CT Chest, Neck, Abdomen and Pelvis</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Incomplete</td>
<td>e.g. no imaging or part imaging</td>
</tr>
<tr>
<td>95</td>
<td>Patient refused investigation</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. patient not for treatment or further investigation</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item(s):
Date Radiological Staging Investigations Completed {Lymphoma}
Date Radiological Staging Investigations Completed {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by the PHS.

Definition: The date that radiological staging investigations were completed by CT

Field Name: SINVESTDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPI: 1

Record the date that ALL items are complete, e.g. if done on separate days then record the final date.

If staging investigations were not completed, record as inapplicable (10/10/1900).

If the exact date is not documented, record as (09/09/1900).

Related Data Item(s):
Radiological Staging Investigations Complete {Lymphoma}
Date of Radiology Request
Date of Radiology Request

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date a CT scan was requested by a Clinician and sent to radiology for CT of chest, abdomen and pelvis ± neck.

Field Name: RADREQDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPI: 1

If more than one CT scan is undertaken, the request date for the final scan should be recorded.

If radiology request not required, record as 10/10/1900 (Not applicable).

If the exact date is not documented, record as 09/09/1900 (Not recorded).

Related Data Item(s):
Radiological Staging Investigations Complete {Lymphoma}
Date Radiological Staging Investigations Completed {Lymphoma}
Date Radiological Staging Investigations Reported

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date radiological staging investigations by CT scan of chest, abdomen and pelvis ± neck are reported.

Field Name: RADREPORTDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPI: 1

If more than one CT scan is undertaken the date of the report of the final CT scan should be recorded to align with date of investigation.

If the date of the CT scan report is not documented record as 09/09/1900 (Not Recorded)

If CT scan is not performed, record as 10/10/1900 (Not applicable).

Related Data Item(s):
Radiological Staging Investigations Complete {Lymphoma}
Date Radiological Staging Investigations Completed {Lymphoma}
Date of Radiology Request
FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record if a FDG-PET/CT (PET/CT) scan was performed for staging and assessment.

Field Name: PETSCAN
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI(s): 1, 3

All newly diagnosed patients with Classical Hodgkin Lymphoma being considered for curative therapy should have a baseline PET CT scan

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>95</td>
<td>Patient refused investigation</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Related Data Items:
Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)
Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)
Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date a PET/CT scan was requested by a Clinician and sent to radiology.

Field Name: PETREQDATE  
Field Type: Date (DD/MM/CCYY)  
Field Length: 10

Notes for Users: Required for QPI(s): 1, 3

Scan should be undertaken within 2 weeks of radiology request.

If radiology request not required, record as 10/10/1900 (Not applicable).

If the exact date is not documented, record as 09/09/1900 (Not recorded).

Related Data Item:  
Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)
Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the date of computed tomography the integrated FDG-PET/CT (PET/CT) scan was performed for staging and assessment.

Field Name: PETDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPI(s): 1, 3
Scan should be undertaken within 2 weeks of radiology request
If the patient has more than one PET/CT scan the date of the first procedure is recorded.
If the exact date of the PET/CT Scan is not documented, record as 09/09/1900 (Not recorded).
If PET/CT scan was not performed record as 10/10/1900 (not applicable).

Related Data Item:
Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)
**Date Integrated FDG-PET/CT (PET/CT) Scan Reported**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date integrated FDG-PET/CT (PET/CT) scan is reported for staging and assessment.

**Field Name:** PETREPORTDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI(s): 1, 3

If more than one PET/CT scan is undertaken the date of the report of the first procedure is recorded to align with date of investigation.

If the date of the PET/CT scan report is not documented record as 09/09/1900 (Not Recorded)

If PET/CT scan is not performed, record as 10/10/1900 (Not applicable).

**Related Data Item(s):**  
FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)  
Date of Radiology Request for FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)  
Date of Integrated FDG-PET/CT (PET/CT) Scan {Lymphoma} (Pre-treatment)
Date MYC Testing Reported [DLBCL/Burkitts Lymphoma]

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date MYC testing was reported using classical cytogenetics or Fluorescence in Situ Hybridization (FISH).

**Field Name:** MYCDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI: 4

Classical cytogenetic or Fluorescence in Situ Hybridization (FISH) analysis is essential for the diagnosis of Burkitt lymphoma.

Rearrangements of MYC in DLBCL/Burkitts are a strong prognostic factor and will guide treatment options and provide important information to help inform patients and carers about the nature of the disease and prognosis.

If the date of the MYC report is unknown record as 09/09/1900 (Not Recorded)

If MYC testing is not required, record as 10/10/1900 (Not applicable).

**Related Data Item:**  
MYC Testing Result [DLBCL/Burkitts Lymphoma]
MYC Testing Result [DLBCL/Burkitts Lymphoma]

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The result of the MYC testing as reported using classical cytogenetics or Fluorescence in Situ Hybridization (FISH).

Field Name: MYCRESULT
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI: 4

Classical cytogenetic or Fluorescence in Situ Hybridization (FISH) analysis is essential for the diagnosis of Burkitt lymphoma.

Rearrangements of MYC in DLBCL/Burkitts are a strong prognostic factor and will guide treatment options and provide important information to help inform patients and carers about the nature of the disease and prognosis.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Positive</td>
<td>e.g. rearranged</td>
</tr>
<tr>
<td>2</td>
<td>Negative</td>
<td>e.g. normal</td>
</tr>
<tr>
<td>3</td>
<td>Failed</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Indeterminate</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>Test not done</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item:
Date MYC Testing Reported [DLBCL/Burkitts Lymphoma]
Date BCL2/6 Testing Reported

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date BCL2/BCL6 testing was reported using classical cytogenetics or Fluorescence in Situ Hybridization (FISH).

Field Name: BCLDATE
Field Type: Date (DD/MM/CCYY)
Field Length: 10

Notes for Users: Required for QPI: 4

In addition to MYC rearrangement, some patients have BCL2 and/or BCL6 rearrangement (double or triple hit lymphomas) which are also strong prognostic factors and will provide information on treatment options, the nature of disease and prognosis.

If the date of the BCL2/BCL6 report is unknown record as 09/09/1900 (Not Recorded)

If BCL2/BCL6 testing is not required, record as 10/10/1900 (Not applicable).

Not applicable and Test not done are both covered by 10/10/1900

Related Data Item:
Location of Diagnosis {Cancer}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The patient's hospital of investigation in which the diagnosis of cancer was first made

Field Name: HOSP
Field Type: Characters
Field Length: 5

Notes for Users: Required for clarifying responsibility for data collection and national comparative analysis.

This will be the hospital / GP surgery where the sample was taken or the hospital at which the patient was managed when the diagnosis was made.

Must be a valid hospital code listed in the national reference file.

Location codes for hospitals are five character codes maintained by PHS and the General Register Office (Scotland). [http://www.natref.scot.nhs.uk/](http://www.natref.scot.nhs.uk/)

Location must be viewed as an address and not a code. If any new locations arise where NHS healthcare is delivered/administered, please ensure that the Reference Files Team at PHS is informed using form LOC-NEW (which can be downloaded from the website below) so that a new code may be issued as appropriate.


The first character denotes the health board, the next three are assigned and the fifth denotes the type of location (H=hospital) e.g.

A111H=Crosshouse Hospital
G107H=Glasgow Royal Infirmary

If a patient was diagnosed through imaging at one hospital but transferred to another for confirmation of the diagnosis, the first hospital should be recorded as the Location of diagnosis.

If location is unknown record as X9999

Related Data Item:
Date of Diagnosis {Cancer}
Date of Diagnosis {Cancer}

**Main Source of Data Item Standard:** The National Audit Cancer Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date on which lymphoma was first diagnosed whether by histology, cytology, immunology or cytogenetics.

**Field Name:** DIAGDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field length:** 10

**Notes for Users:** Required for national survival analysis and national comparative analysis.

Diagnosis of lymphoma is usually determined by histology.

If the exact date is not documented, record as 09/09/1900.

The date recorded is the date the procedure was performed, not the date the report was issued.

**Related Data Item:**

Date BCL2/6 Testing Reported

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date BCL2/BCL6 testing was reported using classical cytogenetics or Fluorescence in Situ Hybridization (FISH).

**Field Name:** BCLDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI: 4

In addition to MYC rearrangement, some patients have BCL2 and/or BCL6 rearrangement (double or triple hit lymphomas) which are also strong prognostic factors and will provide information on treatment options, the nature of disease and prognosis.

If the date of the BCL2/BCL6 report is unknown record as 09/09/1900 (Not Recorded)

If BCL2/BCL6 testing is not required, record as 10/10/1900 (Not applicable).

Not applicable and Test not done are both covered by 10/10/1900
Related Data Item:

Location of Diagnosis {Cancer}
Virological Testing (1-3)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record of the result of virological testing for, hepatitis B, hepatitis C and HIV.

Field Name: HEPB
  HEPC
  HIV
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI: 11

Virological tests recorded should be those undertaken as part of the diagnostic process.

Hepatitis B includes core antibody and surface antigen. If both tests are not carried out this should be recorded as 89, Test not done. If both tests are carried out and either core or surface is recorded as positive this should be coded as 01 Positive.

Results for all 3 blood tests should be recorded separately.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>Test not done</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused investigation</td>
<td>Patient not undergoing SACT</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>Patient not undergoing SACT</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item:
Date of Virological Testing (1-3)
**Date of Virological Testing (1-3)**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** A record of the date that virological testing, hepatitis B, hepatitis C and HIV was carried out.

**Field Name:** HEPBDATE  
HEPCDATE  
HIVDATE

**Field Type:** Date (DD/MM/CCYY)  
**Field length:** 10

**Notes for Users:** Required for QPI: 11

Dates for each individual blood test should be recorded separately.

If the date of the test is unknown record as 09/09/1900.

If test is not carried out record as Not Applicable 10/10/1900.

If both core antibody and surface antigen tests are not carried out record as test not carried out, i.e Not Applicable 10/10/1900.

**Related Data Item:**  
Virological Testing
Date Discussed by Haematology Care Team (MDT)

**Common name:** Date discussed by multidisciplinary team (MDT)

**Main source of data standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This denotes the date the Haematology care team meeting (also known as the multidisciplinary team) was held to discuss the management of the patient's care.

**Field Name:** MDTDATE

**Field Type:** Date (DD/MM/CCYY)

**Field Length:** 10

**Notes for Users:** Required for QPI: 5

A cancer multidisciplinary care team may include surgeons, oncologists, haemat-oncologists, radiologists, pathologists, nurses, physiotherapists and others relevant to the treatment of a specific cancer. The team meets on a regular basis to discuss optimal patient management. Documentation of the discussion should be included in the case-note or other formal documentation.

The first MDT meeting should be recorded.

If the date of the MDT meeting is unknown record as 09/09/1900 or if the patient has not been discussed by the MDT, record as Not applicable 10/10/1900.

**Related Data Item(s):**
Date Discussed by Specialist MDT [Primary Cutaneous Lymphoma]

**Main source of data standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This denotes the date the specialist MDT meeting which included representation from pathology, dermatology, oncology ± haemato-oncology was held to discuss the management of the patient's primary cutaneous lymphoma.

**Field Name:** SPECMDTDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:**

A specialist MDT for patients with primary cutaneous lymphoma facilitates clinico-pathological correlation, which is very important in this group of conditions where treatment is multi-faceted. Furthermore it allows for consolidation of expertise in this rare condition which will help develop robust diagnosis and management.

The first specialist MDT meeting should be recorded.

If the date of the MDT meeting is unknown record as 09/09/1900 or if the patient has not been discussed by the MDT, record as Not applicable 10/10/1900.

**Related Data Item(s):**
COVID 19 Impact

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record of whether COVID 19 has impacted on treatment decisions.

Field Name: COVID
Field Type: Integer
Field Length: 2

Notes for Users: Required for national survival analysis and national comparative analysis.

The COVID 19 pandemic will have an impact on the patient pathways of some patients, potentially affecting the treatment they will receive. This may affect treatment decisions from the outset or plans may change part way through treatment. MDTs will record when the recommendations of the MDT for management are made on the basis of emergency COVID 19 management guideline and differ from what would otherwise be advised.

Where there is a record of a patients treatment being amended due to the emergency COVID 19 management guidelines elsewhere, for example amendments to treatment after MDT discussion, then this can also be recorded under ‘Yes – other’, however it is acknowledged that this information may not be complete.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes - plan developed by MDT</td>
<td>MDT record treatment as determined by emergency COVID 19 management guidelines from the outset</td>
</tr>
<tr>
<td>2</td>
<td>Yes - plan amended by MDT</td>
<td>MDT record amendment to existing treatment plan due to emergency COVID 19 management guidelines</td>
</tr>
<tr>
<td>3</td>
<td>Yes – Other</td>
<td>Other record of amendment to treatment due to emergency COVID 19 management guidelines e.g. clinic letter about alteration of treatment plan</td>
</tr>
<tr>
<td>4</td>
<td>No</td>
<td>No evidence of patient treatment being affected by COVID 19</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td>Where documentation of part of the patient pathway is unavailable, e.g. for patients diagnosed outwith NHS Scotland, or where the patient moves away while treatment is still ongoing</td>
</tr>
</tbody>
</table>
**WHO/ ECOG Performance Status**

**Main Source of Data Item Standard:** WHO (World Health Organisation) and ECOG (Eastern Cooperative Oncology Group)

**Definition:** An overall assessment of the functional/physical performance of the patient.

**Field Name:** PSTATUS  
**Field Type:** Integer  
**Field length:** 1

**Notes for Users:** Required for survival analysis

The WHO/ECOG performance status is a grade on a five point scale (range 0 to 4) at the time of investigation in which '0' denotes normal activity and '4' a patient who is 100% bedridden. If it is not documented do not deduce from other information and record as 'Not recorded'.

This item may occur more than once throughout a patient’s record.

This field relates to pre-treatment performance status i.e. at the time of the MDT closest to actual treatment.

If the performance status falls between two scores, record the higher value i.e. the worst performance status.

**Codes and values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Fully active, able to carry on all pre-disease performance without restriction</td>
</tr>
<tr>
<td>1</td>
<td>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light housework, office work</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory and capable of self care but unable to carry out any work activities: up and about more than 50% of waking hours</td>
</tr>
<tr>
<td>3</td>
<td>Capable of only limited self care, confined to bed or chair more than 50% of waking hours</td>
</tr>
<tr>
<td>4</td>
<td>Completely disabled, cannot carry on any self care, totally confined to bed or chair</td>
</tr>
<tr>
<td>9</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>
Treatment Intent

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This is intent of treatment that was carried out.

Field Name: INTENT
Field Type: Integer
Field length: 2

Notes for Users: Required for QPI(s): 1, 2, 3, 4

This information should be recorded at MDT, clinical letter or within electronic prescribing systems, this should not be deduced.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Curative</td>
<td>Treatment given with the potential for cure (radical treatment). E.g. radical chemotherapy such as R-CHOP and ABVD.</td>
</tr>
<tr>
<td>3</td>
<td>Supportive care only</td>
<td>Care aimed at symptom control and sustaining the patients and/or carers ability to cope with a medical condition.</td>
</tr>
<tr>
<td>4</td>
<td>Watch and Wait</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Non-curable</td>
<td>Any treatment given for the control of symptoms resulting from the cancer e.g. surgery, radiotherapy, or Systemic Anti-Cancer Therapy (SACT). This includes low grade lymphoma being treated with the intention of reaching durable remission.</td>
</tr>
<tr>
<td>94</td>
<td>Patient died before treatment</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused treatment</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>
Type of First Cancer Treatment {Lymphoma}

**Common name:** Mode of first treatment

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This denotes the first specific treatment modality administered to a patient.

**Field Name:** FIRSTTREATTYPE  
**Field Type:** Integer  
**Field length:** 2

**Notes for Users:** Required for QPI: 5

For any particular modality it is the first treatment and not specifically the definitive treatment i.e. this does not include purely diagnostic biopsies such as incisional biopsies, needle biopsies or core biopsies.

Record patients as having ‘supportive care only’ if a decision was taken not to give the patient any active treatment as part of their primary therapy.

No active treatment includes watchful waiting and supportive care but not palliative chemotherapy and/or radiotherapy.

Steroids etc should not be recorded as first treatment if more substantive treatment such as radiotherapy, chemotherapy or surgery is given. If no further treatment is given, then record as supportive care

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Explanatory notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Radiotherapy</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Endoscopic</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Hormone therapy</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Supportive care</td>
<td>No active treatment</td>
</tr>
<tr>
<td>11</td>
<td>Other therapy</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Watchful waiting</td>
<td>No active treatment</td>
</tr>
<tr>
<td>15</td>
<td>Chemoradiotherapy</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Chemoimmunotherapy</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Patient died before treatment</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused all therapies</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Item:**  
Date of First Cancer Treatment
**Date of First Cancer Treatment {Lymphoma}**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This denotes the date the type of first cancer treatment was given to the patient.

**Field Name:** FIRSTTREATDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI(s): 1, 3

This field should be recorded for all patients including those with supportive care only (‘No active treatment’) (see below).

If type of first cancer treatment is ‘supportive care only’, the date recorded should be the first date the decision was taken not to give the patient treatment as part of their primary therapy. Where this has subsequently been confirmed at MDT, the date of MDT should be recorded. The aim of this date is to distinguish between patients who have initially had no treatment but receive some therapy when symptoms develop.

The date recorded should be that of the first type of cancer treatment.

If the exact date is not documented, record as 09/09/1900 (Not recorded).

If the patient died before treatment or the patient refused treatment, record as 10/10/1900 (Not applicable).

**Related Data Item:**  
Type of First Cancer Treatment
Section 3: Pathology
Date of Issue of Pathology Report {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This is the date that the pathology report was issued.

Field Name: DPATHREP  
Field Type: Date (DD/MM/CCYY)  
Field Length: 10

Notes for Users: Required for QPI: 5

This is the date of the actual report date (as documented on the pathology form) and not the date approved by the laboratory.

If more than one biopsy has been carried out for diagnostic purposes then the earliest report date which confirms a diagnosis of lymphoma should be recorded.

If the exact date of pathology report is not known, record as 09/09/1900 (Not recorded).

If no biopsy has been performed, record as 10/10/1900 (Not applicable).

Notes by Users:
Morphology of Tumour {Lymphoma}


Definition: This is the morphology of the tumour according to the International Classification of Diseases for Oncology (ICD-O(3)).

Field Name: MORPHOL
Field Type: Characters
Field Length: 6

Notes for Users: Required for QPI(s): 1-5, 7-9, 11, 12
If not recorded, record as 9999/9 (Not recorded).

Morphology codes are shown below. This list is not exhaustive and if a code is not on the list please contact mailto:phs.canceraudit@phs.scot for advice.

ICD-O(3) code ‘96983’ has been subdivided into ‘A’ (Follicular Lymphoma Grade 3A) and ‘B’ (Follicular Lymphoma Grade 3B) to meet QPI requirements.

Lymphoma Morphology Codes

Mature B-cell Neoplasms

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>96893</td>
<td>Splenic Marginal Zone Lymphoma</td>
</tr>
<tr>
<td>95913A</td>
<td>Splenic B-cell Lymphoma/Leukaemia, Unclassifiable</td>
</tr>
<tr>
<td>95913B</td>
<td>Splenic Diffuse Red Pulp Small B-cell Lymphoma</td>
</tr>
<tr>
<td>96713</td>
<td>Lymphoplasmacytic Lymphoma</td>
</tr>
<tr>
<td>97613</td>
<td>Waldenstrom Macroglobulinaemia</td>
</tr>
<tr>
<td>96993A</td>
<td>Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT-Lymphoma)</td>
</tr>
<tr>
<td>96993B</td>
<td>Nodal Marginal Zone Lymphoma</td>
</tr>
<tr>
<td>96993C</td>
<td>Paediatric nodal marginal zone lymphoma</td>
</tr>
<tr>
<td>96903A</td>
<td>Follicular Lymphoma</td>
</tr>
<tr>
<td>96913</td>
<td>Follicular Lymphoma Grade 2</td>
</tr>
<tr>
<td>96953</td>
<td>Follicular Lymphoma Grade 1</td>
</tr>
<tr>
<td>96983A</td>
<td>Follicular Lymphoma Grade 3A</td>
</tr>
<tr>
<td>96983B</td>
<td>Follicular Lymphoma Grade 3B</td>
</tr>
<tr>
<td>96953A</td>
<td>Duodenal-type follicular lymphoma</td>
</tr>
<tr>
<td>96903B</td>
<td>Testicular follicular lymphoma</td>
</tr>
<tr>
<td>96903C</td>
<td>Paediatric-type follicular lymphoma</td>
</tr>
<tr>
<td>96983C</td>
<td>Large B-cell lymphoma with IRF4 rearrangement</td>
</tr>
<tr>
<td>95973</td>
<td>Primary Cutaneous Follicle Centre Lymphoma</td>
</tr>
<tr>
<td>96733</td>
<td>Mantle Cell Lymphoma</td>
</tr>
<tr>
<td>96803A</td>
<td>Diffuse Large B-cell Lymphoma NOS</td>
</tr>
<tr>
<td>96803F</td>
<td>Diffuse Large B-cell Lymphoma, Germinal centre B-cell subtype</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>96803G</td>
<td>Diffuse Large B-cell Lymphoma, Activated B-cell subtype</td>
</tr>
<tr>
<td>96883</td>
<td>T-cell Histiocyte-rich Large B-cell Lymphoma</td>
</tr>
<tr>
<td>96803B</td>
<td>Primary Diffuse Large B-cell Lymphoma of the CNS</td>
</tr>
<tr>
<td>96803C</td>
<td>Primary Cutaneous DLBCL, Leg Type</td>
</tr>
<tr>
<td>96803D</td>
<td>EBV-positive DLBCL, NOS</td>
</tr>
<tr>
<td>96803E</td>
<td>DLBCL Associated with Chronic Inflammation</td>
</tr>
<tr>
<td>96803H</td>
<td>Fibrin-associated diffuse large B-cell lymphoma</td>
</tr>
<tr>
<td>97661</td>
<td>Lymphomatoid Granulomatosis, grade 1,2</td>
</tr>
<tr>
<td>97663</td>
<td>Lymphomatoid Granulomatosis, grade 3</td>
</tr>
<tr>
<td>96793</td>
<td>Primary Mediastinal (Thymic) Large B-cell Lymphoma</td>
</tr>
<tr>
<td>97123</td>
<td>Intravascular Large B-cell Lymphoma</td>
</tr>
<tr>
<td>97373</td>
<td>ALK-Positive Large B-Cell Lymphoma</td>
</tr>
<tr>
<td>97353</td>
<td>Plasmablastic Lymphoma</td>
</tr>
<tr>
<td>97383</td>
<td>HHV8-positive DLBCL, NOS</td>
</tr>
<tr>
<td>96783</td>
<td>Primary Effusion Lymphoma</td>
</tr>
<tr>
<td>96873A</td>
<td>Burkitt Lymphoma</td>
</tr>
<tr>
<td>96873B</td>
<td>Burkitt-like lymphoma with 11q aberration</td>
</tr>
<tr>
<td>96803I</td>
<td>High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements</td>
</tr>
<tr>
<td>96803J</td>
<td>High-grade B-cell lymphoma, NOS</td>
</tr>
<tr>
<td>95963</td>
<td>B-cell Lymphoma, Unclassifiable with Features Intermediate between DLBCL and Classic Hodgkin Lymphoma</td>
</tr>
</tbody>
</table>

**Mature T- and NK-Cell Neoplasms**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>97243</td>
<td>Systemic EBV-positive T-cell Lymphoma of Childhood</td>
</tr>
<tr>
<td>97193</td>
<td>Extranodal NK/T Cell Lymphoma, Nasal Type</td>
</tr>
<tr>
<td>97173A</td>
<td>Enteropathy-associated T-cell Lymphoma</td>
</tr>
<tr>
<td>97173B</td>
<td>Monomorphous epitheliotopic intestinal T-cell lymphoma</td>
</tr>
<tr>
<td>97173C</td>
<td>Intestinal T-cell lymphoma, NOS</td>
</tr>
<tr>
<td>97163</td>
<td>Hepatosplenic T-cell Lymphoma</td>
</tr>
<tr>
<td>97083</td>
<td>Subcutaneous Panniculitis-like T-cell Lymphoma</td>
</tr>
<tr>
<td>97003</td>
<td>Mycosis Fungoides</td>
</tr>
<tr>
<td>97013</td>
<td>Sezary Syndrome</td>
</tr>
<tr>
<td>97183</td>
<td>Primary Cutaneous Anaplastic Large Cell Lymphoma (C-ALCL)</td>
</tr>
<tr>
<td>97263</td>
<td>Primary Cutaneous Gamma-delta T-cell Lymphoma</td>
</tr>
<tr>
<td>97093A</td>
<td>Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma</td>
</tr>
<tr>
<td>97093B</td>
<td>Primary Cutaneous acral CD8-positive T-cell Lymphoma</td>
</tr>
<tr>
<td>97091</td>
<td>Primary Cutaneous CD4-positive /small/Medium T-cell Lymphoproliferative disorder</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>97023</td>
<td>Peripheral T-cell Lymphoma, NOS</td>
</tr>
<tr>
<td>97053</td>
<td>Angioimmunoblastic T-cell Lymphoma</td>
</tr>
<tr>
<td>97023</td>
<td>Follicular T-cell lymphoma</td>
</tr>
<tr>
<td>97023</td>
<td>Nodal peripheral T-cell lymphoma with T follicular helper phenotype</td>
</tr>
<tr>
<td>97143</td>
<td>Anaplastic Large Cell Lymphoma, (ALCL) ALK Positive</td>
</tr>
<tr>
<td>97153A</td>
<td>Anaplastic Large Cell Lymphoma, ALK Negative</td>
</tr>
<tr>
<td>97153B</td>
<td>Breast implant-associated anaplastic large cell lymphoma</td>
</tr>
</tbody>
</table>

**Uncertain if B or T Cell**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>95913</td>
<td>Malignant Lymphoma, Non-Hodgkin, Not Otherwise Specified</td>
</tr>
</tbody>
</table>

**Hodgkin Lymphomas**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>96593</td>
<td>Nodular Lymphocyte Predominant Hodgkin Lymphoma</td>
</tr>
<tr>
<td>96503</td>
<td>Classic Hodgkin Lymphoma (incl PTLD)</td>
</tr>
<tr>
<td>96633</td>
<td>Nodular Sclerosis Classic Hodgkin Lymphoma</td>
</tr>
<tr>
<td>96513</td>
<td>Lymphocyte-rich Classic Hodgkin Lymphoma</td>
</tr>
<tr>
<td>96523</td>
<td>Mixed Cellularity Classic Hodgkin Lymphoma</td>
</tr>
<tr>
<td>96533</td>
<td>Lymphocyte-depleted Classic Hodgkin Lymphoma</td>
</tr>
</tbody>
</table>

**Immunodeficiency-Associated Lymphoproliferative Disorders**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99711</td>
<td>Post-transplant Lymphoproliferative Disorder, Polymorphic</td>
</tr>
</tbody>
</table>
Number of Nodal Sites {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The number of nodal sites involved with disease

Field Name: NONODAL
Field Type: Integer
Field Length: 2

Notes for Users: Required for survival analysis.

Number of nodal sites should be stated by Clinician/ MDT.

If the number of nodal sites is unknown record as 99 (Not Recorded).

If number of nodal sites is not required, record as 96 (Not applicable).

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1-4</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>≥ 5</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable/not assessed</td>
<td>not staged</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

List of Nodal Sites:

- CERVICAL
- COELIAC
- PRE-AURICULAR
- PARA-AORTIC
- POST-AURICULAR
- PORTA HEPATIS
- PAROTID
- MESENERIC
- SUBMANDIBULAR
- RETROPERITONEAL
- SUBMAXILLARY
- ILIAC
- OCCIPITAL
- INGUINAL
- SUBMENTAL
- FEMORAL
- SUPRACLAVICULAR
- EPITROCHELEAR / BRACHIAL
- INFRACLAVICULAR
- OTHER NODAL
- AXILLARY
- THYMUS
- PECTORAL
- MEDIASTINUM
- INTERCOSTAL
- NASOPHARYNX
- LUNG HILAR
- WALDEYERS RING
- RETROCRURAL
- SPLEEN
- SPLENIC HILAR
Number of Extranodal Sites {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The number of extranodal sites involved with disease

Field Name: EXNODAL
Field Type: Integer
Field Length: 2

Notes for Users: Required for survival analysis.

Number of extranodal sites should be stated by Clinician/ MDT.

If the number of extranodal sites is unknown record as 99 (Not Recorded).

If number of extranodal sites is not required, record as 96 (Not applicable).

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>&gt;1</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable/not assessed</td>
<td>not staged</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

List of Extranodal Sites:

<table>
<thead>
<tr>
<th>Site</th>
<th>Site</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>BONE</td>
<td>LARGE BOWEL</td>
<td>CHEST WALL</td>
</tr>
<tr>
<td>BRAIN</td>
<td>RECTUM</td>
<td>EAR</td>
</tr>
<tr>
<td>SPINAL CORD</td>
<td>THYROID</td>
<td>EXTRADURAL</td>
</tr>
<tr>
<td>SKIN</td>
<td>SINUS</td>
<td>LACRIMAL</td>
</tr>
<tr>
<td>SUBCUTANEOUS</td>
<td>NOSE</td>
<td>PERITONEUM</td>
</tr>
<tr>
<td>CERVIX</td>
<td>TONGUE</td>
<td>LIVER</td>
</tr>
<tr>
<td>OVARY</td>
<td>OROPHARYNX</td>
<td>PANCREAS</td>
</tr>
<tr>
<td>VAGINA</td>
<td>PALATE</td>
<td>GALLBLADDER</td>
</tr>
<tr>
<td>LABIA</td>
<td>GUM</td>
<td>ADRENAL</td>
</tr>
<tr>
<td>TESTIS</td>
<td>BUCCAL</td>
<td>PAROTID SALIVARY GLAND</td>
</tr>
<tr>
<td>UTERUS</td>
<td>LARYNX</td>
<td>OMENTUM</td>
</tr>
<tr>
<td>PROSTATE</td>
<td>TRACHEA</td>
<td>MUSCLE</td>
</tr>
<tr>
<td>BLADDER</td>
<td>BRONCHUS</td>
<td>BLOOD BONE MARROW</td>
</tr>
<tr>
<td>KIDNEY</td>
<td>LUNG</td>
<td>EXTRA NODAL</td>
</tr>
<tr>
<td>OESOPHAGUS</td>
<td>PLEURA</td>
<td>SUBMANDIBULAR SALIVARY GLAND</td>
</tr>
<tr>
<td>STOMACH</td>
<td>BREAST</td>
<td>ORBIT</td>
</tr>
<tr>
<td>SMALL BOWEL</td>
<td>CARDIAC</td>
<td>EYELID</td>
</tr>
</tbody>
</table>
Serum LDH

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The level of lactate dehydrogenase (LDH) as measured at the time the patient was investigated for cancer.

Field Name: SERLDH
Field Type: Integer
Field Length: 2

Notes for Users: Required for survival analysis

Record the last available result prior to starting treatment.

This information should be available in the MDT notes.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal or Below</td>
</tr>
<tr>
<td>2</td>
<td>Raised</td>
</tr>
<tr>
<td>3</td>
<td>Not performed</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>
**Haemoglobin**

**Main source of data standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The level of haemoglobin (Hb) detected in the patient’s blood when they were investigated for cancer.

**Field Name:** HAEMOGLOB  
**Field Type:** Integer  
**Field Length:** 4

**Notes for Users:** Required for survival analysis

Hb should be recorded in g/l.

The level recorded should normally be the first result after referral and before treatment.

This information should be available in the MDT notes.

If the test was not performed, record as 1010 (Not applicable)

If no level is recorded then record as 9999 (Not recorded).
**Albumin at Diagnosis**

**Main source of data standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The serum level of albumin at the time the patient was investigated for cancer.

**Field Name:** ALBUMIN  
**Field Type:** Integer  
**Field Length:** 4

**Notes for Users:** Required for survival analysis

Albumin should be recorded in g/l.

The level recorded should normally be the first result after referral and before treatment. This information should be available in the MDT notes.

If the test was not performed, record as 1010 (Not applicable)

If no level is recorded then record as 9999 (Not recorded).
WBC Total

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The total white blood cell count in the patient’s blood when they were first investigated for cancer.

Field Name: WBCTOT
Field Type: Number (nnn.n)
Field Length: 5

Notes for Users: Required for survival analysis

The level recorded should normally be the first result after referral and before treatment. This information should be available in the MDT notes.

WBC total should be recorded in $10^9/l$.

If no blood count is recorded then record as 999.9 (Not recorded).
WBC Differential – Lymphocytes

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The lymphocyte count in the patient’s blood when they were first investigated for cancer.

Field Name: WBCLYMPHO
Field Type: Number (nnn.nn)
Field Length: 6

Notes for Users: Required for survival analysis

A WBC differential is a measure of an individual component (lymphocytes) of the total white blood cell count.

The level recorded should normally be the first result after referral and before treatment.

Lymphocytes should be recorded in $10^9/l$.

If no blood count is recorded then record as 999.99 (Not recorded).
Section 4: Classification
**IPI (Lymphoma)**

**Main source of data standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The International Prognostic Index (IPI) is for patients with high grade non-Hodgkin lymphoma.

**Field Name:** IPI  
**Field Type:** Integer  
**Field Length:** 2

**Notes for Users:** Required for survival analysis


It is calculated as follows:

- Age >60years
- WHO/ECOG >=2
- Cotswold III, IV (Ann Arbor)
- Extranodal Disease > 1 site
- LDH Raised

Score 1 for each of the above factors.

Cotswold staging will be utilised to determine IPI.

IPI is a calculated field. This should ensure no interpretation of clinical information by audit staff and provides background data for sub-analysis.

All Hodgkin lymphoma patients, or those with known distant metastasis who would not require this prognostic index calculated code as Not applicable Non-Hodgkin lymphoma with known distant metastasis or where not recorded in clinical notes code as Not known.

If result is unclear please seek clarification from Clinician. Record the calculated value.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0-1</td>
<td>Low Risk</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>Intermediate/Low treatment Distant metastases</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>Intermediate/High</td>
</tr>
<tr>
<td>4</td>
<td>4-5</td>
<td>High Risk treatment Distant metastases</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable treatment Distant metastases</td>
<td>Patient does not have high grade follicular NHL</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded treatment Distant metastases</td>
<td></td>
</tr>
</tbody>
</table>
FLIPI {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This is a 5 factor prognostic index for patients with low grade follicular non-Hodgkin lymphoma.

Field Name: FLIPI
Field Type: Integer
Field Length: 2

Notes for Users:

FLIPI is calculated as follows:

Age >=60 years
Clinical Stage III, IV
LDH Raised
Hb <120g/l
Number of Nodal Sites >=5

Score 1 for each of the above factors.

FLIPI is a calculated field. This should ensure no interpretation of clinical information by audit staff and provides background data for sub-analysis.

If result is unclear please seek clarification from Clinician.

Record the calculated value.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0-1</td>
<td>Good</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>Intermediate</td>
</tr>
<tr>
<td>3</td>
<td>&gt;=3</td>
<td>Intermediate/High</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable treatment</td>
<td>Distant metastases</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded treatment</td>
<td>Distant metastases</td>
</tr>
</tbody>
</table>
Hasenclever Index for Hodgkin Disease {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This is a prognostic index for patients with advanced Hodgkin disease.

Field Name: HASENINDEX
Field Type: Integer
Field Length: 2

Notes for Users:

This is a prognostic score for advanced Hodgkin Disease (The New England Journal of Medicine: 1998;339:1506-14).

Factors required for calculation:
- Serum albumin <40g/l (serum)
- Haemoglobin <105 g/l
- Male sex
- Stage IV disease
- Age ≥ 45 yrs
- White cell count ≥15,000/mm3 (≥15 x 10^9/l)
- Lymphocyte count <600/mm3 (<0.6x10^9/l)

Score 1 for each of the above factors.

Stage IV indicates diffuse or disseminated involvement of one or more extralymphatic organs, including any involvement of the liver, bone marrow, or nodular involvement of the lungs.

This is a calculated field. This should ensure no interpretation of clinical information and provides background data for sub-analysis.

Record the calculated value.
If any of the elements of the score are missing the index cannot be calculated and should be recorded as ‘Not recorded’ (99).

If the patient does not have Hodgkin Disease, record as ‘Not applicable’ (96).
Cotswold Clinical Stage {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the clinical stage of the patient prior to the start of their treatment for lymphoma according to the Cotswold classification.

Field Name: COTSWOLD
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI: 12

The Cotswold Staging Classification is also known as the Ann Arbor Staging Classification, or the Revised Ann Arbor System.

Treatment depends both on the stage of the disease and whether or not symptoms are present. Stages are labelled with an A if no symptoms are present. If symptoms are present, drenching sweats, unexplained weight loss, and fatigue, the stage is labelled with a B.

This information should be recorded at MDT.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>I</td>
<td>The disease is confined to one lymph node area (eg cervical, axillary, mediastinal) or lymphoid structure (eg spleen, Waldeyer’s ring).</td>
</tr>
<tr>
<td>2</td>
<td>IE</td>
<td>The disease extends from the one lymph node area to adjacent regions. Single extra lymphatic site as only site of disease</td>
</tr>
<tr>
<td>3</td>
<td>II</td>
<td>The disease is in two or more lymph node areas on one side of the diaphragm (the muscle below the lungs) eg bihilar disease.</td>
</tr>
<tr>
<td>4</td>
<td>IIE</td>
<td>The disease extends to adjacent regions of at least one of these nodes. Extra nodal site which is contiguous or proximal to a known site.</td>
</tr>
<tr>
<td>5</td>
<td>III</td>
<td>The disease is in lymph node areas on both sides of the diaphragm</td>
</tr>
<tr>
<td>6</td>
<td>IIIE</td>
<td>The disease extends into adjacent areas or organs.</td>
</tr>
<tr>
<td>7</td>
<td>IIISE</td>
<td>The disease extends into adjacent areas or organs and/or the spleen.</td>
</tr>
<tr>
<td>8</td>
<td>IV</td>
<td>The disease has spread from the lymphatic system to one or more other organs, such as the bone marrow or liver.</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>Not staged / Not applicable for Primary Cutaneous Lymphoma.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item(s):
IPI {Lymphoma}
B Symptoms {Lymphoma}
B Symptoms {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The presence of one or more B symptoms in the patient at presentation for investigation of the cancer.

Field Name: BSYMPTOM
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI:12

The following symptoms are classified as ‘B’ Symptoms:

- Night sweats - should be drenching
- Weight loss - should exceed 10% body weight in the last 6 months
- Fever - requires careful history and, ideally, confirmation by thermometry

Alcohol pain and itch are not ‘B’ symptoms.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>

Related Data Item(s):
Manchester Stage {Lymphoma}

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This denotes the clinical stage of the patients with gastrointestinal lymphoma prior to the start of their treatment.

Field Name: MANCHESTER
Field Type: Integer
Field Length: 2

Notes for Users: Required for survival analysis
Gastrointestinal lymphomas are defined as tumours originating in the stomach, small or large intestine.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ia</td>
<td>Tumour confined to one area of the gastrointestinal tract without penetration of the serosa.</td>
</tr>
<tr>
<td>2</td>
<td>Ib</td>
<td>Multiple tumours confined to the gastrointestinal tract without penetration of the serosa.</td>
</tr>
<tr>
<td>3</td>
<td>IIa</td>
<td>Tumour with local nodes radiologically/histologically involved (gastric or mesenteric).</td>
</tr>
<tr>
<td>4</td>
<td>IIb</td>
<td>Tumour with perforation and/or adherence to adjacent structures.</td>
</tr>
<tr>
<td>5</td>
<td>IIc</td>
<td>Tumour with perforation and peritonitis.</td>
</tr>
<tr>
<td>6</td>
<td>III</td>
<td>Tumour with widespread nodal involvement (para-aortic or more distant nodes).</td>
</tr>
<tr>
<td>7</td>
<td>IV</td>
<td>Disseminated disease involving extra-lymphatic tissues not adjacent to the tumour (eg liver, bone marrow, bone, lung etc).</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>Lymphoma not gastrointestinal</td>
</tr>
<tr>
<td>98</td>
<td>Not staged</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>
Bulk Disease

Main source of data standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: This indicates whether bulk disease was present at the time the patient was investigated for cancer.

Field Name: BULKDISEASE
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI: 12

This should have been assessed after referral and before treatment for cancer.

Bulk disease is defined as by Cotswold criteria (Lister et al, 1989).

The bulk of palpable lymph nodes will be defined by the largest dimension (cm) of a single node or conglomerate nodal mass in each region of involvement, using CT, MRI, lymphography, or ultrasonography. A node or nodal mass must be 10cm or greater to be recorded as ‘bulky’.

The overall amount of disease in the spleen will not be quantitatively assessed using imaging procedures. Lesions within the liver or spleen may be measured for assessment or response but the measurements will not be recorded for staging purposes.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes (≥10cm)</td>
</tr>
<tr>
<td>2</td>
<td>No Bulk Disease</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
</tr>
<tr>
<td>98</td>
<td>Not assessed</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
</tr>
</tbody>
</table>
Section 5: Oncology Treatment


**Location Code {Oncology Treatment}**

**Common Name(s):** Location

**Main Source of Data Item Standard:** Derived from SMR data standards.

**Definition:** This is the reference number of any building or set of buildings where events pertinent to NHS Scotland take place. Locations include hospitals, health centres, GP surgeries, clinics, NHS board offices, nursing homes, schools and patient/client’s home.

**Field Name:** HOSPNONSURG  
**Field Type:** Characters  
**Field Length:** 5

**Notes for Users:** Required for regional/national analysis

The hospital in which the patient received the majority of SACT Treatment.

Location codes for hospitals are five character codes maintained by PHS and the General Register Office (Scotland). [http://www.natref.scot.nhs.uk/](http://www.natref.scot.nhs.uk/)

Location must be viewed as an address and not a code. If any new locations arise where NHS healthcare is delivered/administered, please ensure that the Reference Files Team at PHS is informed using form LOC-NEW (which can be downloaded from the website below) so that a new code may be issued as appropriate. [http://www.isdscotland.org/Products-and-Services/Data-Definitions-and-References/National-Reference-Files/](http://www.isdscotland.org/Products-and-Services/Data-Definitions-and-References/National-Reference-Files/)

The first character denotes the health board, the next three are assigned and the fifth denotes the type of location (H=hospital) e.g.

A111H=Crosshouse Hospital  
G107H=Glasgow Royal Infirmary

Information about location should be electronically stored, managed and transferred using the relevant location code. IT systems should allow the recording and display of locations on the user interface as the relevant location name and associated address, etc.

If the location code is not documented, record as X9999.

If oncological treatment has not been performed or the patient has refused, record the hospital where clinic was attended.
Radiotherapy {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record if external beam radiotherapy has been administered for the treatment of the cancer.

Field Name: RADIOTYPE1  
Field Type: Integer  
Field length: 2

Notes for Users:

Combined treatments may be administered concurrently/synchronously e.g. chemotherapy and radiotherapy.

All treatments given as part of the initial treatment plan should be recorded, including consolidation radiotherapy.

Treatment received for initial management and not treatment of recurrence or relapse. If the patients type of first treatment was ‘supportive care only’ or ‘watchful waiting’ then subsequently proceeds to active treatment at a later date, only record if treatment occurs within 6 months of diagnosis.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>93</td>
<td>Patient contraindicated in treatment</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Patient died before treatment</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused treatment</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Items:
Location Code {Oncology Treatment}  
Date Treatment Started {Cancer} (Radiotherapy)  
Date Treatment Completed {Cancer} (Radiotherapy)
Date Treatment Started {Cancer} (Radiotherapy)

Main Source of Data Item Standard: The National Audit Cancer Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date cancer treatment course commenced.

Field Name: RSRTDATE1
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users:

This is the first fraction of a course of radiotherapy.

For the purposes of national audit, only radiotherapy given as part of the primary treatment plan should be recorded. Palliative radiotherapy to other (metastatic) sites is only recorded if part of the initial treatment plan.

If the date radiotherapy started is unknown, record as 09/09/1900.

If radiotherapy has not been given or the patient has refused radiotherapy, record as not applicable, 10/10/1900.

Related Data Items:
Location Code {Oncology Treatment}
Radiotherapy {Lymphoma}
Date Treatment Completed {Cancer} (Radiotherapy)
Date Treatment Completed {Cancer} (Radiotherapy)

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:**
The date cancer treatment course ended.

**Field Name:** RCOMPDATE1
**Field Type:** Date (DD/MM/CCYY)
**Field Length:** 10

**Notes for Users:** Required for QPI: 2

This is the last fraction of a course of radiotherapy.

It should be noted this can be the same day as the day the therapy started.

If the date treatment completed is unknown, record as 09/09/1900.

If treatment has not been given, record as not applicable, 10/10/1900.

**Related Data Item(s):**
Location Code {Oncology Treatment}
Radiotherapy {Lymphoma}
Date Treatment Started {Cancer} (Radiotherapy)
Type of Systemic Anti-Cancer Therapy (SACT)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The type of course of cytotoxic or biological drugs administered for the treatment of the cancer. Cytotoxic drugs are drugs which destroy cells.

Field Name: SACT1
Field Type: Integer
Field Length: 2

Notes for Users: Required for QPI: 2, 11

Treatment given as part of initial/first line treatment should be recorded, i.e. treatment for relapsed or recurrent disease should not be recorded.

If patient is receiving chemotherapy in combination with radiotherapy, record as option 1 and detail radiotherapy information in relevant radiotherapy field.

Treatment received for initial management and not treatment of recurrence or relapse. If the patient’s type of first treatment was ‘supportive care only’ or ‘watchful waiting’ then subsequently proceeds to active treatment at a later date, only record if treatment occurs within 6 months of diagnosis.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chemotherapy</td>
<td>Chemotherapy treatment may be given in combination with radiotherapy or alone.</td>
</tr>
<tr>
<td>2</td>
<td>Chemoimmunotherapy</td>
<td>Chemotherapy given in combination with immunotherapy, e.g. R-CHOP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chemoimmunotherapy will include any combination of chemotherapy and Rituximab.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Systemic Therapy Agent codes 3,7,8a,9a,10,11,13,14,15,19,21a,27,29)</td>
</tr>
<tr>
<td>6</td>
<td>Single Agent Immunotherapy</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Patient died before SACT treatment</td>
<td>i.e. Patient who died before receiving planned SACT treatment</td>
</tr>
<tr>
<td>95</td>
<td>Patient refused SACT treatment</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. Systemic therapy not given.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Items:
Location Code {Oncology Treatment}
Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer}
Total Number of Systemic Anti-Cancer Therapy Cycles Planned (SACT)

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The planned total number of cycles of SACT treatment to be given to the patient, regardless of the number of cycles the patient receives.

**Field Name:** PLSACTCYC1  
**Field Type:** Integer  
**Field Length:** 4

**Notes for Users:** Required for survival analysis

This is for all chemotherapy regimens.

There is no requirement to complete this field for maintenance immunotherapy.

If systemic therapy not given record as ‘1010’ (Not applicable).

If number of cycles has not been recorded or unknown, record as ‘9999’ (Not recorded).

**Related Data Item(s):**  
- Location Code {Oncology Treatment}  
- Type of Systemic Anti-Cancer Therapy (SACT)  
- Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT)
Total Number of Systemic Anti-Cancer Therapy Cycles Given (SACT)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record of the total number of cycles of SACT treatment given to the patient.

Field Name: SACTCYC1
Field Type: Integer
Field Length: 4

Notes for Users:

There is no requirement to complete this field for maintenance immunotherapy.

If systemic therapy not given record as ‘1010’ (Not applicable).

If number of cycles has not been recorded or unknown, record as ‘9999’ (Not recorded).

Related Data Item(s):
Location Code {Oncology Treatment}
Type of Systemic Anti-Cancer Therapy (SACT)
Total Number of Systemic Anti-Cancer Therapy Cycles Planned (SACT)
Anti-B Cell Monoclonal Antibody Therapy {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: A record of whether the patient received anti-B cell monoclonal antibody therapy.

Field Name: ANTIBCELL
Field Type: Integer
Field length: 2

Notes for Users:

Rituximab is a type of anti-B cell monoclonal antibody therapy. There are also other types of anti-B cell monoclonal antibody therapy in addition to rituximab e.g. obinutuzumab. This field should only be used to record any types of anti-B cell monoclonal antibody therapy which is given as first line treatment to patients with lymphoma.

This replaces the field ‘Rituximab {Lymphoma} which was previously included in the dataset.

Chemotherapy drugs can be given in or outwith the context of a clinical trial.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

e.g. NA where SACT is not given and NO when SACT is given but it is not rituximab.

List of SACT regimens containing Rituximab (includes but is not limited to):

- Rituximab
- Bendamustine, rituximab
- R-CODOX-M (Rituximab + CODOX-M)
- R-CODOX-M/IVAC (Rituximab + CODOX-M/IVAC)
- Fludarabine, rituximab
- Fludarabine, Cyclophosphamide and Rituximab (FCR)
- Rituximab/CVP
- Rituximab/EPOCH
- Rituximab/hyper CVAD
- R-CEOP
<table>
<thead>
<tr>
<th>Related Data Items:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of Systemic Anti-Cancer Therapy (SACT)</td>
</tr>
<tr>
<td>Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer}</td>
</tr>
<tr>
<td>Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer}</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug Combinations</th>
</tr>
</thead>
<tbody>
<tr>
<td>R-GCVP</td>
</tr>
<tr>
<td>R-ESHAP (Rituximab + ESHAP)</td>
</tr>
<tr>
<td>Rituximab maintenance</td>
</tr>
<tr>
<td>R-DHAP (Rituximab + DHAP)</td>
</tr>
<tr>
<td>R-IVE (Rituximab + IVE)</td>
</tr>
<tr>
<td>R-CHOP (Rituximab + CHOP)</td>
</tr>
</tbody>
</table>
**Rituximab + CHOP (Lymphoma)**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** Rituximab and CHOP (R-CHOP) used in combination to treat lymphoma.

**Field Name:** RCHOP  
**Field Type:** Integer  
**Field length:** 2

**Notes for Users:**  
Chemotherapy drugs can be given in or outwith the context of a clinical trial.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not Applicable</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Items:**  
Type of Systemic Anti-Cancer Therapy (SACT)
ABVD Chemotherapy {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: ABVD chemotherapy regimen used in the first line treatment of Hodgkin Lymphoma.

Field Name: ABVD
Field Type: Integer
Field length: 2

Notes for Users: Required for QP: 12

ABVD chemotherapy is a regimen which includes Doxorubicin, Bleomycin, Vinblastine and Dacarbazine. Note this type of chemotherapy is used specifically to treat Hodgkin Lymphoma.

Chemotherapy drugs can be given in or outwith the context of a clinical trial.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. patient does not have Hodgkin Lymphoma.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Items:
BEACOPP/BEACOPDac Chemotherapy {Lymphoma}

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** BEACOPP or BEACOPDac chemotherapy regimens used in the first line treatment of Hodgkin Lymphoma.

**Field Name:** BEACOPP  
**Field Type:** Integer  
**Field length:** 2

**Notes for Users:** Required for QP: 12

BEACOPP and BEACOPDac are chemotherapy regimens which include the following:

**BEACOPP** - Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisolone.

**BEACOPDac** - Bleomycin, Cyclophosphamide, Dacarbazine, Doxorubicin, Etoposide, Prednisolone and Vincristine

Note these types of chemotherapy are used specifically to treat Hodgkin Lymphoma.

Chemotherapy drugs can be given in or outwith the context of a clinical trial.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. patient does not have Hodgkin Lymphoma.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Items:**
Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date systemic anti cancer therapy course commenced.

Field Name: SACTDATE1
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users: Required for QPI(s): 4, 11

This is the first dose of the first cycle of a course of chemotherapy or immunotherapy.

If the date SACT started is unknown, record as 09/09/1900.

If SACT has not been given or the patient has refused SACT, record as not applicable, 10/10/1900.

Related Data Items:
Location Code {Oncology Treatment}
Type of Systemic Anti-Cancer Therapy (SACT)
Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer}
Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date cancer treatment course ended.

Field Name: SACTENDATE1
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users:

This is the first day of the last cycle of a course of SACT.

It should be noted this can be the same day as the day the therapy started.

There is no requirement to complete this field for maintenance immunotherapy.

If the date treatment started is unknown, record as 09/09/1900.

If SACT has not been given or the patient has refused SACT, record as not applicable, 10/10/1900.

Related Data Items:
Location Code {Oncology Treatment}
Type of Systemic Anti-Cancer Therapy (SACT)
Date Started Systemic Anti-Cancer Therapy (SACT)
Date of Final Systemic Anti-Cancer Therapy (SACT) Treatment

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date of the final SACT treatment given.

Field Name: SACTFINALDATE1
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users: Required for QPI: 2

This is the last day of the last cycle of a course of SACT.

There is no requirement to complete this field for maintenance immunotherapy.

If the date of final treatment is unknown, record as 09/09/1900.

If SACT has not been given or the patient has refused SACT, record as not applicable, 10/10/1900.

Related Data Items:
Date Started Systemic Anti-Cancer Therapy (SACT) {Cancer}
Date Completed Systemic Anti-Cancer Therapy (SACT) {Cancer}
Date Started Cycle 2 ABVD/BEACOPP/BEACOPDac Chemotherapy {Lymphoma}

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** The date cycle 2 of ABVD or BEACOPP or BEACOPDac chemotherapy commenced.

**Field Name:** ABVDDATE2  
**Field Type:** Date (DD/MM/CCYY)  
**Field length:** 10

**Notes for Users:** Required for QPI: 12

This is the first dose of the second cycle of a course of ABVD or BEACOPP or BEACOPDac chemotherapy. Note these types of chemotherapy are used specifically to treat Hodgkin Lymphoma.

If the date of the second cycle of ABVD/BEACOPP/BEACOPDac is unknown, record as 09/09/1900.

If the patient has not undergone ABVD/BEACOPP/BEACOPDac chemotherapy, record as not applicable, 10/10/1900.

**Related Data Items:**
Date Started Cycle 3 Chemotherapy {Lymphoma}

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date cycle 3 of chemotherapy commenced.

Field Name: CHEMDATE3
Field Type: Date (DD/MM/CCYY)
Field length: 10

Notes for Users: Required for QPI: 12

This is the first dose of the third cycle of a course of chemotherapy.

If the date of the third cycle of chemotherapy is unknown, record as 09/09/1900.

If the patient has not undergone chemotherapy, record as not applicable, 10/10/1900.

Related Data Items:
Date of Interim PET CT Scan {Lymphoma}

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This denotes the date of the interim PET CT scan that was performed for assessment of response to ABVD or BEACOPP or BEACOPDac chemotherapy.

**Field Name:** ABVDPETDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI: 12

PET CT Scans to assess treatment response to ABVD or BEACOPP or BEACOPDac chemotherapy should be carried out after 2 cycles of chemotherapy treatment (and prior to commencement of cycle 3). Note this type of chemotherapy is used specifically to treat Hodgkin Lymphoma.

If the exact date of the interim PET/CT Scan is not documented, record as 09/09/1900 (Not recorded).

If interim PET/CT scan was not performed record as 10/10/1900 (not applicable).

If the patient dies during treatment record as 08/08/1900

**Related Data Items:**
**Date Interim PET CT Scan Reported**

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by the PHS.

**Definition:** The date the interim PET CT scan is reported for assessment of response to ABVD or BEACOPP or BEACOPDac chemotherapy.

**Field Name:** ABVDREPORTDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI: 12

PET CT Scans to assess treatment response to ABVD or BEACOPP or BEACOPDac chemotherapy should be carried out after 2 cycles of chemotherapy treatment (and prior to commencement of cycle 3).

If the date of the interim PET CT scan report is not documented record as 09/09/1900 (Not Recorded)

If interim PET/CT scan is not performed, record as 10/10/1900 (Not applicable).

**Related Data Item(s):**
Maintenance Therapy {Lymphoma}

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** Maintenance treatment with anti-B cell monoclonal antibody therapy.

**Field Name:** MAINT  
**Field Type:** Integer  
**Field length:** 2

**Notes for Users:**

Maintenance therapy can be given after initial treatment for patients whose disease has responded well to first line treatment.

This is specific to Follicular Lymphoma only: Rituximab for 2 years post chemotherapy. Maintenance immunotherapy occurs immediately after chemotherapy for a period of up to 2 years. At present Rituximab is the only immunotherapy agent which will be given in this indication.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>Patient died before treatment</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. patient does not have Follicular Lymphoma.</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Data Definitions for the National Minimum Core Dataset for Lymphoma.  
Developed by ISD Scotland, 2013  
Page 74
Bone Marrow Transplant

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** A record if the patient received a bone marrow transplant as first line of treatment.

**Field Name:** BONETR  
**Field Type:** Integer  
**Field Length:** 2

**Notes for Users:**

Bone marrow transplant for first line treatment is rare.

Only record if treatment was first line.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td>e.g. Bone marrow transplant not given</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Items:**
Date of Radiological Imaging Post Treatment Completed {Lymphoma}

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by the PHS.

**Definition:** The date that radiological imaging was completed by CT of the chest, abdomen and pelvis ± neck, or PET CT, at the end of treatment.

**Field Name:** POSTIMAGDATE  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI: 2  
Completed at the end of induction treatment.

CT scans within 6 weeks of the last day of the final cycle of chemotherapy or within 3 months of radiotherapy will be calculated within the measurability as an end of treatment scan. Date should be recorded.

Complete imaging is of the CT of chest, abdomen and pelvis ± neck (and no other combination), or PET CT,

If imaging was not completed or not done, record as 10/10/1900 (Not applicable).

If the exact date is not documented, record as 09/09/1900 (not recorded)

Patients who have not finished treatment or if patient dies during treatment record as 08/08/1900

**Related Data Item(s):**
Section 6: Clinical Trial Entry
Patient Entered into Clinical Trial (Lymphoma)

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: 
An indication of whether or not the patient received treatment within the context of a clinical trial.

Field Name: TRIAL 
Field Type: Integer 
Field Length: 2

Notes for Users:
This relates only to participation in clinical trials which may be national or international multi-centred trials.

The majority of non-commercial multi-centred trials available in Scotland are National Cancer Research Network (NCRN) badged or equivalent.

Some academic and university units may have ongoing local trials which should not be included here. These can be recorded on local trials databases.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No trial available</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>No trial offered</td>
<td>Trial available but not offered to patient</td>
</tr>
<tr>
<td>4</td>
<td>Not eligible for trial</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>Patient refused clinical trial</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>Patient died before treatment</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Items:
Section 7: Follow-up
Response Post First Treatment

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** A record of what the patient’s best response was as determined by the clinician at the post treatment assessment.

**Field Name:** FTRESPONS  
**Field Type:** Integer  
**Field length:** 2

**Notes for Users:** Required for survival analysis

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Complete remission (CR)/</td>
<td>No signs or symptoms of disease</td>
</tr>
<tr>
<td></td>
<td>Complete Remission Unconfirmed (CRU)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Partial Remission (PR)</td>
<td>50% decrease in tumour size</td>
</tr>
<tr>
<td>3</td>
<td>Stable Disease</td>
<td>Neither partial response nor progressive disease</td>
</tr>
<tr>
<td>4</td>
<td>Progressive Disease/Refractory Disease</td>
<td>50% increase in disease</td>
</tr>
<tr>
<td>96</td>
<td>Not applicable</td>
<td>e.g. Watch and wait / Patient died before treatment</td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

**Related Data Item(s):**
Post-Treatment Assessment Date

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date on which the patient had their post-treatment assessment.

Field Name: POSTTREATDATE
Field Type: Date (DD/MM/CCYY).
Field Length: 10

Notes for Users: Required for survival analysis

If patient did not have a post-treatment assessment, record as 10/10/1900 (not applicable).

Post treatment assessment date should be the date of radiological evidence i.e. date of CT post primary therapy whether chemo/radiotherapy etc., if no radiology undertaken/available the date of the clinic appointment should be recorded.

If the exact date is not documented, record as 09/09/1900 (Not recorded).

Related Data Item(s):
Follow-up Status

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: An indicator of the patient’s vital status as determined by the clinician at follow-up.

Field Name: FUSTATUS
Field Type: Integer
Field length: 2

Notes for Users: Required for survival analysis

It is essential that follow-status has a follow-up date recorded, without which time to relapse cannot be assessed.

Codes and Values:

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Continued first remission</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Stable Disease</td>
<td>e.g. Watch and wait</td>
</tr>
<tr>
<td>3</td>
<td>Relapsed Disease</td>
<td>Includes watch and wait with progressive disease</td>
</tr>
<tr>
<td>4</td>
<td>Moved away</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Patient deceased</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Not recorded</td>
<td></td>
</tr>
</tbody>
</table>

Related Data Item(s): Follow-up Date/Date of Relapse/Progression
Follow-up Date/Date of Relapse/Progression

Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

Definition: The date on which the patient was last seen at follow-up for patients with continued first remission or stable disease, or date of relapse/progression, for patients with relapsed/progressive disease.

Field Name: FUDATE  
Field Type: Date (DD/MM/CCYY).  
Field Length: 10

Notes for Users: Required for survival analysis

This should be collected annually for a minimum of 5 years.

The follow-up period is calculated from the date of diagnosis to the date of follow-up.

If patient has relapsed/progressive disease the date of relapse/progression should be recorded rather than follow up date.

If the exact date is not documented, or data are required for reporting within the year, record as 09/09/1900 (Not recorded).

If the patient was not seen for follow up, record as 10/10/1900

Related Data Item(s):  
Follow-up Status  
Date of Diagnosis {Cancer}
Transformation to High Grade

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** An indicator as to whether a patient’s lymphoma, if relapsed, has transformed from low to high grade lymphoma.

**Field Name:** TRANS  
**Field Type:** Integer  
**Field length:** 2

**Notes for Users:**

In low grade lymphomas the cancerous lymphocytes multiply slowly. This kind of lymphoma therefore accumulates at a slow rate over time. This is in contrast to high-grade lymphomas, in which the cells are multiplying very quickly and the lymphoma accumulates rapidly over a matter of weeks.

Transformation can happen with any low grade lymphoma.

**Codes and Values:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Value</th>
<th>Explanatory Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Not Applicable</td>
<td>Already high grade disease e.g. DLBCL</td>
</tr>
</tbody>
</table>

**Related Data Item(s):**
Section 8: Death Details
Date of Death

**Main Source of Data Item Standard:** The National Cancer Audit Datasets developed by the regional Cancer Networks supported by PHS.

**Definition:** This is the certified date of death as recorded by the General Register Office (Scotland) (GRO(S)).

**Field Name:** DOD  
**Field Type:** Date (DD/MM/CCYY)  
**Field Length:** 10

**Notes for Users:** Required for QPI(s): 4, 7 and for survival analysis.

If the exact date is not documented, record as 09/09/1900.

If the patient is alive use the code 10/10/1900 (Not applicable).

**Codes and Values:** N/A

**Related Data Items:**